<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id>
<journal-id journal-id-type="pmc">ploscomp</journal-id><journal-title-group>
<journal-title>PLoS Computational Biology</journal-title></journal-title-group>
<issn pub-type="ppub">1553-734X</issn>
<issn pub-type="epub">1553-7358</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PCOMPBIOL-D-13-00274</article-id>
<article-id pub-id-type="doi">10.1371/journal.pcbi.1003217</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories>
<title-group>
<article-title>Modeling the Effect of APC Truncation on Destruction Complex Function in Colorectal Cancer Cells</article-title>
<alt-title alt-title-type="running-head">A Model for β-Catenin Destruction Complex Function</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Barua</surname><given-names>Dipak</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hlavacek</surname><given-names>William S.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
</contrib-group>
<aff id="aff1"><label>1</label><addr-line>Theoretical Biology and Biophysics Group, Theoretical Division and Center for Nonlinear Studies, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America</addr-line></aff>
<aff id="aff2"><label>2</label><addr-line>Department of Biology, University of New Mexico, Albuquerque, New Mexico, United States of America</addr-line></aff>
<aff id="aff3"><label>3</label><addr-line>Clinical Translational Research Division, Translational Genomics Research Institute, Phoenix, Arizona, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Shvartsman</surname><given-names>Stanislav</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group>
<aff id="edit1"><addr-line>Princeton University, United States of America</addr-line></aff>
<author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">wish@lanl.gov</email></corresp>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn>
<fn fn-type="con"><p>Conceived and designed the experiments: DB WSH. Performed the experiments: DB WSH. Analyzed the data: DB WSH. Contributed reagents/materials/analysis tools: DB WSH. Wrote the paper: DB WSH.</p></fn>
</author-notes>
<pub-date pub-type="collection"><month>9</month><year>2013</year></pub-date>
<pub-date pub-type="epub"><day>26</day><month>9</month><year>2013</year></pub-date>
<volume>9</volume>
<issue>9</issue>
<elocation-id>e1003217</elocation-id>
<history>
<date date-type="received"><day>13</day><month>2</month><year>2013</year></date>
<date date-type="accepted"><day>10</day><month>7</month><year>2013</year></date>
</history>
<permissions>
<copyright-year>2013</copyright-year>
<copyright-holder>Barua, Hlavacek</copyright-holder><license xlink:type="simple"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions>
<abstract>
<p>In colorectal cancer cells, APC, a tumor suppressor protein, is commonly expressed in truncated form. Truncation of APC is believed to disrupt degradation of β—catenin<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e001" xlink:type="simple"/></inline-formula>, which is regulated by a multiprotein complex called the destruction complex. The destruction complex comprises APC, Axin, β—catenin<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e002" xlink:type="simple"/></inline-formula>, serine/threonine kinases, and other proteins. The kinases <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e003" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e004" xlink:type="simple"/></inline-formula>, which are recruited by Axin, mediate phosphorylation of β—catenin<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e005" xlink:type="simple"/></inline-formula>, which initiates its ubiquitination and proteosomal degradation. The mechanism of regulation of β—catenin<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e006" xlink:type="simple"/></inline-formula> degradation by the destruction complex and the role of truncation of APC in colorectal cancer are not entirely understood. Through formulation and analysis of a rule-based computational model, we investigated the regulation of β—catenin<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e007" xlink:type="simple"/></inline-formula> phosphorylation and degradation by APC and the effect of APC truncation on function of the destruction complex. The model integrates available mechanistic knowledge about site-specific interactions and phosphorylation of destruction complex components and is consistent with an array of published data. We find that the phosphorylated truncated form of APC can outcompete Axin for binding to β—catenin<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e008" xlink:type="simple"/></inline-formula>, provided that Axin is limiting, and thereby sequester β—catenin<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e009" xlink:type="simple"/></inline-formula> away from Axin and the Axin-recruited kinases <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e010" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e011" xlink:type="simple"/></inline-formula>. Full-length APC also competes with Axin for binding to β—catenin<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e012" xlink:type="simple"/></inline-formula>; however, full-length APC is able, through its SAMP repeats, which bind Axin and which are missing in truncated oncogenic forms of APC, to bring β—catenin<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e013" xlink:type="simple"/></inline-formula> into indirect association with Axin and Axin-recruited kinases. Because our model indicates that the positive effects of truncated APC on β—catenin<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e014" xlink:type="simple"/></inline-formula> levels depend on phosphorylation of APC, at the first 20-amino acid repeat, and because phosphorylation of this site is mediated by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e015" xlink:type="simple"/></inline-formula>, we suggest that <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e016" xlink:type="simple"/></inline-formula> is a potential target for therapeutic intervention in colorectal cancer. Specific inhibition of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e017" xlink:type="simple"/></inline-formula> is predicted to limit binding of β—catenin<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e018" xlink:type="simple"/></inline-formula> to truncated APC and thereby to reverse the effect of APC truncation.</p>
</abstract>
<abstract abstract-type="summary"><title>Author Summary</title>
<p>We asked the question, how can the effects of APC truncation, a very common mutation in colorectal cancer, be understood and reversed? We addressed this question by formulating a computational model for destruction complex function that incorporates site-specific details about protein-protein interactions and protein phosphorylation and examined the differences in predicted behaviors when APC is full length, as in normal cells, and truncated, as in colorectal cancer cells. Our model offers an explanation for how and why destruction complex function is altered by APC truncation. The model indicates that phosphorylation of the first 20-amino acid repeat in APC (which is usually the only 20-amino acid repeat that remains in truncated forms of APC) together with the absence of SAMP repeats (missing entirely because of truncation) allows truncated APC to act as a diversion sink. In other words, phosphorylated APC can outcompete Axin for binding to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e019" xlink:type="simple"/></inline-formula>, provided Axin is limiting, and thereby prevent <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e020" xlink:type="simple"/></inline-formula> from associating with Axin and the Axin-associated kinases <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e021" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e022" xlink:type="simple"/></inline-formula>, which initiate phosphorylation-dependent degradation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e023" xlink:type="simple"/></inline-formula>. Thus, the model identifies inhibition of APC phosphorylation, which is mediated by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e024" xlink:type="simple"/></inline-formula>, as a potential means by which the oncogenic effect of APC truncation could be reversed.</p>
</abstract>
<funding-group><funding-statement>This work was supported in part by NIH grants R01GM076570 and P50GM085273. DB acknowledges support from the Center for Nonlinear Studies at Los Alamos National Laboratory, which is operated for the US Department of Energy under contract DE-AC52-06NA25396. WSH acknowledges support from the Randy Pausch Scholars Program, which is sponsored by the TGen Foundation, Howard Young, and the Global Cure National Advisory Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="18"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e025" xlink:type="simple"/></inline-formula> (CTNNB1) is a key signaling protein in the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e026" xlink:type="simple"/></inline-formula> pathway <xref ref-type="bibr" rid="pcbi.1003217-Clevers1">[1]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Nusse1">[2]</xref>, a regulator of cadherin cell adhesion molecules <xref ref-type="bibr" rid="pcbi.1003217-Burgess1">[3]</xref>, and a regulator of the Tcf and Lef family of transcription factors <xref ref-type="bibr" rid="pcbi.1003217-Behrens1">[4]</xref>–<xref ref-type="bibr" rid="pcbi.1003217-Zhurinsky1">[7]</xref>. In mesenchymal cells, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e027" xlink:type="simple"/></inline-formula> levels increase when a Wnt ligand binds a cell-surface Frizzled (Fz)-family receptor. Activation of the Wnt/<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e028" xlink:type="simple"/></inline-formula> pathway (transiently) inhibits proteosome-mediated degradation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e029" xlink:type="simple"/></inline-formula>. Wnt binding also has other important effects on <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e030" xlink:type="simple"/></inline-formula>, including regulation of phosphorylation state and redistribution of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e031" xlink:type="simple"/></inline-formula> within subcellular compartments. In colorectal cancer cells, normal control of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e032" xlink:type="simple"/></inline-formula> degradation is disrupted, resulting in elevated levels of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e033" xlink:type="simple"/></inline-formula>.</p>
<p>Cellular degradation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e034" xlink:type="simple"/></inline-formula> is regulated by (in our view) oligomeric protein complexes, which have diverse compositions but common features; these complexes are often collectively referred to as the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e035" xlink:type="simple"/></inline-formula> destruction complex <xref ref-type="bibr" rid="pcbi.1003217-Peifer1">[8]</xref>–<xref ref-type="bibr" rid="pcbi.1003217-Stamos1">[10]</xref>. The destruction complex, which characteristically contains <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e036" xlink:type="simple"/></inline-formula> and two scaffold proteins, Axin (axis inhibition protein, AXIN1) and APC (adenomatous polyposis coli protein), mediates phosphorylation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e037" xlink:type="simple"/></inline-formula> by recruiting <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e038" xlink:type="simple"/></inline-formula> (glycogen synthetase <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e039" xlink:type="simple"/></inline-formula>, GSK3B) and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e040" xlink:type="simple"/></inline-formula> (casein kinase <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e041" xlink:type="simple"/></inline-formula>, CSNK1A1) <xref ref-type="bibr" rid="pcbi.1003217-Dajani1">[11]</xref>–<xref ref-type="bibr" rid="pcbi.1003217-Aberle1">[15]</xref>. These kinases, upon binding Axin, catalyze phosphorylation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e042" xlink:type="simple"/></inline-formula> on specific serine and threonine residues. Phosphorylation of Ser-45 by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e043" xlink:type="simple"/></inline-formula> and subsequent phosphorylation of Ser-33, Ser-37, and Thr-41 by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e044" xlink:type="simple"/></inline-formula> initiates ubiquitination and proteosome-mediated degradation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e045" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003217-Liu1">[12]</xref>–<xref ref-type="bibr" rid="pcbi.1003217-Aberle1">[15]</xref>. The destruction complex also recruits PP2A, a multimeric protein phosphatase, which opposes the action of kinases. It has been suggested that activation of Wnt/<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e046" xlink:type="simple"/></inline-formula> signaling destabilizes the destruction complex by sequestering Axin in complexes with activated Fz receptors <xref ref-type="bibr" rid="pcbi.1003217-Cliffe1">[16]</xref>–<xref ref-type="bibr" rid="pcbi.1003217-Cong1">[18]</xref>. However, details about the early events in Wnt/<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e047" xlink:type="simple"/></inline-formula> signaling are still emerging <xref ref-type="bibr" rid="pcbi.1003217-Li1">[19]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Hernndez1">[20]</xref>. In colorectal cancer cells, the destruction complex member APC is often truncated <xref ref-type="bibr" rid="pcbi.1003217-Markowitz1">[21]</xref>. An important effect of APC truncation is believed to be a perturbation of the interactions amongst proteins comprising the destruction complex that alters regulation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e048" xlink:type="simple"/></inline-formula> degradation, perhaps by destabilizing the destruction complex in a way similar to the destabilization brought about by Wnt signaling.</p>
<p>The interactions responsible for assembly of the destruction complex are complex and are mediated by multiple functional sites within the member proteins of the destruction complex. The characteristic core of the destruction complex can be viewed as a ternary complex that forms through interactions of APC, Axin, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e049" xlink:type="simple"/></inline-formula>. <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e050" xlink:type="simple"/></inline-formula> contains twelve ARM (Armadillo) repeats, allowing it to bind both APC and Axin. In particular, ARM repeats 3 and 4 constitutively bind a central region of Axin <xref ref-type="bibr" rid="pcbi.1003217-Xing1">[22]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Sakanaka1">[23]</xref> as well as a phosphorylated 20-amino acid (20-aa) repeat region of APC <xref ref-type="bibr" rid="pcbi.1003217-Xing2">[24]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Liu2">[25]</xref>. There are total of seven 20-aa repeats in this region. <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e051" xlink:type="simple"/></inline-formula> ARM repeats 5–9 constitutively bind three 15-amino acid (15-aa) repeats in the N-terminal region of APC <xref ref-type="bibr" rid="pcbi.1003217-EklofSpink1">[26]</xref>. APC contains three SAMP (serine-alanine-methionine-proline) repeats, which bind the RGS (regulator of G protein signaling) domain of Axin <xref ref-type="bibr" rid="pcbi.1003217-Spink1">[27]</xref>. These interactions connect the three core proteins of the destruction complex (APC, Axin, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e052" xlink:type="simple"/></inline-formula>) and enable each protein to bind the other two core proteins, possibly within a closed/cyclic ternary complex. A cyclic complex would presumably be highly stable, because dissociation of such a complex would require the sequential break up of two protein-protein interactions.</p>
<p>Stability of the destruction complex may be important for its function as a platform for phosphorylation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e053" xlink:type="simple"/></inline-formula>, and other proteins. The destruction complex mediates phosphorylation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e054" xlink:type="simple"/></inline-formula> by allowing Axin to colocalize the kinases <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e055" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e056" xlink:type="simple"/></inline-formula> with their substrate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e057" xlink:type="simple"/></inline-formula>. Axin contains binding sites for both <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e058" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003217-Dajani1">[11]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Hedgepeth1">[28]</xref> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e059" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003217-Liu1">[12]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Sobrado1">[29]</xref>. Interestingly, the destruction complex is also thought to mediate phosphorylation of APC by colocalizing another kinase, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e060" xlink:type="simple"/></inline-formula> (CSNK1E), with APC <xref ref-type="bibr" rid="pcbi.1003217-Ha1">[30]</xref>, although it is not known which protein in the destruction complex recruits <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e061" xlink:type="simple"/></inline-formula>. <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e062" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e063" xlink:type="simple"/></inline-formula> together mediate phosphorylation at the 20-aa repeat region of APC <xref ref-type="bibr" rid="pcbi.1003217-Ha1">[30]</xref>. Recall that this region in APC, when phosphorylated, mediates interaction with a site in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e064" xlink:type="simple"/></inline-formula> that also interacts with Axin <xref ref-type="bibr" rid="pcbi.1003217-Xing1">[22]</xref>–<xref ref-type="bibr" rid="pcbi.1003217-Liu2">[25]</xref>. Thus, phosphorylated APC and Axin compete for binding to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e065" xlink:type="simple"/></inline-formula>. The outcome of this competition is perhaps dependent on stability of the destruction complex.</p>
<p>Much of what we know about the functional effects of APC truncation has come from studies of a human colon adenocarcinoma cell line (SW480). SW480 cells express a truncated form of APC termed APC1338, which contains only the first 1,338 amino acids of the full-length protein <xref ref-type="bibr" rid="pcbi.1003217-Kimelman1">[9]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Munemitsu1">[31]</xref>. APC1338 contains all three 15-aa repeats and the first 20-aa repeat, but is devoid of the remaining six 20-aa repeats and the SAMP repeats, which bind Axin <xref ref-type="bibr" rid="pcbi.1003217-Kimelman1">[9]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Munemitsu1">[31]</xref>. Therefore, a model can be conceptualized wherein assembly of the functional destruction complex cannot be completed in the absence of interaction between APC1338 and Axin, leading to decreased phosphorylation, ubiquitination, and degradation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e066" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003217-Nusse1">[2]</xref>. However, an absence of SAMP repeats in APC does not prevent direct binding of Axin to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e067" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003217-Xing1">[22]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Sakanaka1">[23]</xref>, and there are some uncertainties about the validity of this model <xref ref-type="bibr" rid="pcbi.1003217-Li1">[19]</xref> because reports from different laboratories have shown that expression of recombinant APC can either promote degradation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e068" xlink:type="simple"/></inline-formula> or have no or little effect, depending on cell type and whether APC is expressed transiently or stably <xref ref-type="bibr" rid="pcbi.1003217-Munemitsu1">[31]</xref>–<xref ref-type="bibr" rid="pcbi.1003217-Faux1">[34]</xref>.</p>
<p>As discussed above, APC plays an important role in destruction complex function. However, APC is a multifunctional protein, subject to numerous post-translational modifications. It is believed to play a role in regulating not only phosphorylation and ubiquitination of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e069" xlink:type="simple"/></inline-formula> but also localization of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e070" xlink:type="simple"/></inline-formula>. There are several pools of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e071" xlink:type="simple"/></inline-formula>: membrane-associated (e.g., complexed with E-cadherin), cytosolic (free, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e072" xlink:type="simple"/></inline-formula> bound and Tcf bound), and nuclear. Other components of the destruction complex are also multifunctional proteins, which can be found in distinct subcellular locations and states. For example, Axin, through self-polymerization mediated by its DIX (dishevelled and axin) domain <xref ref-type="bibr" rid="pcbi.1003217-SchwarzRomond1">[35]</xref>, localizes to cytoplasmic puncta. We will not consider these complexities, but they are mentioned at this point to caution the reader about the limitations of our study.</p>
<p>Here, our focus will be on APC regulation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e073" xlink:type="simple"/></inline-formula> phosphorylation within an idealized destruction complex, taken to comprise a ternary complex of APC, Axin, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e074" xlink:type="simple"/></inline-formula> with 1∶1∶1 stoichiometry. We will consider the site-specific details of the interactions amongst these proteins, because these details are relevant for understanding how the interactions of APC, Axin, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e075" xlink:type="simple"/></inline-formula> are perturbed by an absence of SAMP repeats in truncated APC (APC1338). We also consider, with less mechanistic resolution, proteins that mediate phosphorylation and dephosphorylation of APC and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e076" xlink:type="simple"/></inline-formula> and degradation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e077" xlink:type="simple"/></inline-formula>. The set of proteins of interest are considered in isolation. Thus, for example, we do not consider <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e078" xlink:type="simple"/></inline-formula> interaction with E-cadherin, or the effects of Wnt. We also do not consider Axin puncta or the DIX domain in Axin. Axin puncta play a role in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e079" xlink:type="simple"/></inline-formula> degradation but are not required for phosphorylation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e080" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003217-Faux2">[36]</xref>.</p>
<p>To investigate the roles of APC and its oncogenic truncated forms in destruction complex function, we formulated a computational model for regulation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e081" xlink:type="simple"/></inline-formula> phosphorylation and degradation using local rules to represent the protein-protein interactions of interest <xref ref-type="bibr" rid="pcbi.1003217-Hlavacek1">[37]</xref>–<xref ref-type="bibr" rid="pcbi.1003217-Faeder2">[39]</xref>. This rule-based approach, ideal for modeling the chemical kinetics of biomolecular interaction networks, allowed us to consider the mechanistic details of protein-protein interactions at the resolution level of functional sites within the proteins of interest. These mechanistic details are complex, as summarized above, and arguably beyond our ability to comprehend without reasoning aids, such the model considered here. Using this model, we interrogated system behavior, which emerges from the states and state changes of protein sites, with the goal of elucidating the distinctive mechanisms by which APC and APC1338 regulate the rate of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e082" xlink:type="simple"/></inline-formula> destruction in normal and SW480 colorectal cancer cells. We also used our model to investigate the functional significance of intracomplex interactions among APC, Axin, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e083" xlink:type="simple"/></inline-formula>, which have the potential to produce a highly stable cyclic ternary complex.</p>
<p>Although APC is a characteristic component of the destruction complex and thought to be important for degradation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e084" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003217-Munemitsu1">[31]</xref>–<xref ref-type="bibr" rid="pcbi.1003217-Faux1">[34]</xref>, our analyses suggest that APC does not promote degradation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e085" xlink:type="simple"/></inline-formula> in a normal cell when overexpressed. However, we do predict that expression of recombinant full-length APC in SW480 cells promotes <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e086" xlink:type="simple"/></inline-formula> degradation, as seen in several studies <xref ref-type="bibr" rid="pcbi.1003217-Munemitsu1">[31]</xref>–<xref ref-type="bibr" rid="pcbi.1003217-Faux1">[34]</xref>. These results are obtained because, according to our model, phosphorylated APC1338 in SW480 cells competes with Axin for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e087" xlink:type="simple"/></inline-formula>. APC1338-mediated separation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e088" xlink:type="simple"/></inline-formula> from Axin reduces phosphorylation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e089" xlink:type="simple"/></inline-formula> by Axin-recruited kinases, and reduced phosphorylation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e090" xlink:type="simple"/></inline-formula> decreases its rate of degradation. In contrast, in normal cells, binding of phosphorylated full-length APC to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e091" xlink:type="simple"/></inline-formula>, in competition with Axin, is not functionally equivalent because Axin can still colocalize with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e092" xlink:type="simple"/></inline-formula> through indirect association via the SAMP repeats in APC, which are missing in APC1338. Because of these results and because <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e093" xlink:type="simple"/></inline-formula> is responsible for phosphorylation of APC (but not <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e094" xlink:type="simple"/></inline-formula>), we identify <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e095" xlink:type="simple"/></inline-formula> as a potential target for therapeutic intervention in colorectal cancer. Inhibition of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e096" xlink:type="simple"/></inline-formula> is predicted to limit sequestration of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e097" xlink:type="simple"/></inline-formula> away from Axin and Axin-associated kinases and thereby to lower <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e098" xlink:type="simple"/></inline-formula> levels in cancer cells expressing truncated APC.</p>
</sec><sec id="s2">
<title>Results</title>
<p>To investigate how the function of the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e099" xlink:type="simple"/></inline-formula> destruction complex changes when APC is mutated, especially as a result of a typical C-terminal truncation that removes the SAMP repeats and all but the first of the 20-aa repeats, we formulated a model (as described below) for full-length APC interactions with other components of the destruction complex. We then used this model and variants corresponding to different mutated forms of APC to predict how <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e100" xlink:type="simple"/></inline-formula> levels and other readouts of system behavior depend on various parameters, such as the abundance of APC or truncated APC. Because APC contains multiple functional components or sites and we are interested in forms of APC containing different subsets of these sites, we formulated a model that tracks the chemical kinetics of the protein-protein interactions of interest with site-specific/structural resolution. This was accomplished by leveraging the rule-based modeling approach <xref ref-type="bibr" rid="pcbi.1003217-Hlavacek1">[37]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Chylek1">[40]</xref>, in which local rules are used to represent biomolecular interactions and their consequences. Modeling with site-specific resolution is difficult with traditional modeling approaches, such as that of ordinary differential equations (ODEs), because of combinatorial complexity <xref ref-type="bibr" rid="pcbi.1003217-Hlavacek2">[41]</xref>, which arises from multisite phosphorylation, multivalent binding, and other common aspects of biomolecular interactions involved in cellular regulation. Combinatorial complexity is a motivating factor for the use of rule-based modeling here.</p>
<sec id="s2a">
<title>Model</title>
<p>We developed a model for APC, Axin, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e101" xlink:type="simple"/></inline-formula> interactions and destruction complex function using the rule-based modeling framework of BioNetGen <xref ref-type="bibr" rid="pcbi.1003217-Hlavacek1">[37]</xref>–<xref ref-type="bibr" rid="pcbi.1003217-Faeder2">[39]</xref> (see <xref ref-type="sec" rid="s4">Materials and Methods</xref>). We considered a base model, corresponding to a normal cell with full-length APC, and several variant forms of the base model. The base model is illustrated in <xref ref-type="fig" rid="pcbi-1003217-g001">Figs. 1</xref> and <xref ref-type="fig" rid="pcbi-1003217-g002">2</xref>. The model is annotated in <xref ref-type="supplementary-material" rid="pcbi.1003217.s004">Text S1</xref> (Supporting Information). Executable BioNetGen input files are provided in the Supporting Information for the base model (<xref ref-type="supplementary-material" rid="pcbi.1003217.s005">Text S2</xref>) and eight variant forms of the base model (<xref ref-type="supplementary-material" rid="pcbi.1003217.s006">Text S3</xref> through <xref ref-type="supplementary-material" rid="pcbi.1003217.s013">Text S10</xref>).</p>
<fig id="pcbi-1003217-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003217.g001</object-id><label>Figure 1</label><caption>
<title>Overview of the signaling proteins and interactions considered in the model.</title>
<p>Panel A is a simplified version of <xref ref-type="fig" rid="pcbi-1003217-g002">Fig. 2</xref>, which follows and goes beyond the diagram shown here by illustrating the functional components of proteins responsible for interactions. Selected protein complexes considered in the model are illustrated in Panels B–D. (A) Proteins are represented by boxes. In the model, five proteins, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e102" xlink:type="simple"/></inline-formula>, APC, Axin, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e103" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e104" xlink:type="simple"/></inline-formula>, are considered explicitly, whereas <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e105" xlink:type="simple"/></inline-formula>, PP2A (not shown), and other proteins are considered implicitly. <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e106" xlink:type="simple"/></inline-formula>, which mediates phosphorylation of APC, and PP2A, which mediates dephosphorylation of APC, are assumed to be constitutively associated with Axin. In the model, their activities are engaged when Axin is in complex with APC. Interactions included in the model are represented by arrows; numbering of arrows is the same as in <xref ref-type="fig" rid="pcbi-1003217-g002">Fig. 2</xref>. The arrows labeled 1–6 represent reversible direct binding interactions. The arrows labeled 7–10 represent catalytic (phosphorylation) interactions (and enzyme-substrate relationships). All phosphorylation events are taken to be reversed by phosphatases. The interaction represented by Arrow 1 is constitutive. The interaction represented by Arrow 2 depends on sequential phosphorylation of APC by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e107" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e108" xlink:type="simple"/></inline-formula> (Arrows 9 and 10). The interactions represented by Arrows 2 and 3 are mutually exclusive, because they involve the same binding site in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e109" xlink:type="simple"/></inline-formula>, i.e., Axin and APC compete for binding to this site. The interaction between APC and Axin represented by Arrow 4 is missing for typical truncated forms of APC (i.e., forms of APC, such as APC1338, missing SAMP repeats). Arrows 5 and 6 represent recruitment of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e110" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e111" xlink:type="simple"/></inline-formula> to Axin. Arrows 7–10 represent phosphorylation reactions mediated by Axin-associated kinases. (B) A binary complex of APC and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e112" xlink:type="simple"/></inline-formula> connected through two distinct protein-protein interfaces. The interactions represented by Arrows 1 and 2 are allowed to occur simultaneously. (C) A complex wherein <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e113" xlink:type="simple"/></inline-formula> is directly bound to Axin via the interaction represented by Arrow 3. Recall that this interaction cannot occur if <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e114" xlink:type="simple"/></inline-formula> is bound to APC via the interaction represented by Arrow 2. (D) A complex containing a linear (vs. cyclic) ternary complex of APC, Axin, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e115" xlink:type="simple"/></inline-formula>. This linear complex is allowed to close and form a cyclic complex via the interaction represented by Arrow 3. Note that the complex depicted here cannot form when APC is truncated such that the interaction represented by Arrow 4 is missing. The model is further described in <xref ref-type="fig" rid="pcbi-1003217-g002">Fig. 2</xref> and <xref ref-type="supplementary-material" rid="pcbi.1003217.s004">Text S1</xref>.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003217.g001" position="float" xlink:type="simple"/></fig><fig id="pcbi-1003217-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003217.g002</object-id><label>Figure 2</label><caption>
<title>Site-specific details of the proteins and interactions considered in the model.</title>
<p>Proteins, interactions, and the functional components that mediate interactions are represented according to the conventions of Chylek et al. <xref ref-type="bibr" rid="pcbi.1003217-Chylek2">[42]</xref>. The numbering of arrows is the same as in <xref ref-type="fig" rid="pcbi-1003217-g001">Fig. 1</xref>. The double-arrowed lines represent reversible binding interactions. The lines ending with an open circle represent enzyme-substrate relationships and point to sites of phosphorylation. In the model, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e116" xlink:type="simple"/></inline-formula> sites Ser-33, Ser-37, and Thr-41, which are <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e117" xlink:type="simple"/></inline-formula> substrates, are lumped together as a single site labeled S33/37. <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e118" xlink:type="simple"/></inline-formula> site Ser-45, which is a <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e119" xlink:type="simple"/></inline-formula> substrate, is labeled S45. In the model, the seven 20-aa repeats of APC are lumped into two distinct sites labeled 1 and 3. For further information about the model, see <xref ref-type="sec" rid="s4">Materials and Methods</xref>. A complete and executable specification of the model is provided in the Supporting Information as a plain-text BioNetGen input file (<xref ref-type="supplementary-material" rid="pcbi.1003217.s005">Text S2</xref>). Note that there is a correspondence between the arrows shown here and the rules of the model (<xref ref-type="supplementary-material" rid="pcbi.1003217.s004">Text S1</xref>). Model parameter values are summarized in <xref ref-type="table" rid="pcbi-1003217-t001">Table 1</xref>.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003217.g002" position="float" xlink:type="simple"/></fig>
<p>In the base model, both explicit and implicit interactions are considered. We explicitly consider the interactions of five signaling proteins (and their isoforms presumed to be functionally equivalent): APC, Axin, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e120" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e121" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e122" xlink:type="simple"/></inline-formula>. We implicitly consider the interactions of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e123" xlink:type="simple"/></inline-formula>, PP2A, other phosphatases, and the proteins responsible for ubiquitination and proteosomal degradation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e124" xlink:type="simple"/></inline-formula>. In <xref ref-type="fig" rid="pcbi-1003217-g002">Fig. 2</xref>, proteins and their interactions are represented with site-specific/structural resolution using the conventions of Chylek et al. <xref ref-type="bibr" rid="pcbi.1003217-Chylek2">[42]</xref>. Briefly, proteins and their functional components are represented by nested boxes. Components excluded from consideration (e.g., the DIX domain of Axin) are not illustrated in <xref ref-type="fig" rid="pcbi-1003217-g002">Fig. 2</xref>. Arrows connecting boxes represent interactions. It should be noted that the visual elements of <xref ref-type="fig" rid="pcbi-1003217-g002">Fig. 2</xref> correspond to the formal elements of our model <xref ref-type="bibr" rid="pcbi.1003217-Chylek2">[42]</xref>: boxes correspond to molecule types and arrows correspond to rules for interactions (<xref ref-type="supplementary-material" rid="pcbi.1003217.s004">Text S1</xref>). Each interaction included in the model is discussed below. The technical details of how these interactions are modeled/represented using rules are explained in <xref ref-type="supplementary-material" rid="pcbi.1003217.s004">Text S1</xref>. See also the <xref ref-type="sec" rid="s4">Materials and Methods</xref> section.</p>
<p>Arrow 1 in <xref ref-type="fig" rid="pcbi-1003217-g002">Fig. 2</xref> represents reversible binding of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e125" xlink:type="simple"/></inline-formula> ARM repeats 5–9 to the 15-aa repeats of APC <xref ref-type="bibr" rid="pcbi.1003217-Xing1">[22]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-EklofSpink1">[26]</xref>. In the model, ARM repeats 5–9 are considered to comprise a single binding site. Likewise, the three 15-aa repeats in APC are considered to comprise a single binding site.</p>
<p>Arrow 2 represents reversible binding of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e126" xlink:type="simple"/></inline-formula> ARM repeats 3 and 4 to phosphorylated APC 20-aa repeats <xref ref-type="bibr" rid="pcbi.1003217-Xing1">[22]</xref>. In the model, ARM repeats 3 and 4 are considered to comprise a single binding site. The seven 20-aa repeats of APC are taken to function as two distinct binding sites, with binding activity of one site considered to be mutually exclusive with binding activity of the other site. The first site (labeled 1) corresponds to the first 20-aa repeat and the second site (labeled 3) corresponds to the third 20-aa repeat. We consider binding of APC to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e127" xlink:type="simple"/></inline-formula> to be mediated by the phosphorylated first repeat when the protein is APC1338 (or a comparable truncated form of APC), and predominantly (exclusively in the model as a simplification) by the phosphorylated third repeat if the protein is full-length APC. This distinction is made because APC1338 contains only the first 20-aa repeat, whereas full-length APC contains all seven 20-aa repeats. Binding of full-length APC to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e128" xlink:type="simple"/></inline-formula> is mediated primarily by the phosphorylated third 20-aa repeat <xref ref-type="bibr" rid="pcbi.1003217-Liu2">[25]</xref> because the phosphorylated third repeat binds with 100- to 1000-fold higher affinity than that of any of the other phosphorylated 20-aa repeats <xref ref-type="bibr" rid="pcbi.1003217-Liu2">[25]</xref>. We take the stoichiometry of a <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e129" xlink:type="simple"/></inline-formula>-APC complex to be 1∶1.</p>
<p>Arrow 3 represents reversible binding of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e130" xlink:type="simple"/></inline-formula> to Axin. ARM repeats 3 and 4 of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e131" xlink:type="simple"/></inline-formula> bind a central region of Axin <xref ref-type="bibr" rid="pcbi.1003217-Xing1">[22]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Sakanaka1">[23]</xref>. As noted before, ARM repeats 3 and 4 also bind the phosphorylated 20-aa repeat region of APC (Arrow 2). Thus, ARM repeats 3 and 4 represent a <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e132" xlink:type="simple"/></inline-formula> binding site recognized by both APC and Axin.</p>
<p>Arrow 4 represents reversible binding of APC to Axin. The three SAMP repeats of APC bind the RGS domain of Axin <xref ref-type="bibr" rid="pcbi.1003217-Spink1">[27]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Kishida1">[43]</xref>. In the model, as a simplification, the SAMP repeats are considered to comprise a single binding site. Thus, we take the stoichiometry of an APC-Axin complex to be 1∶1.</p>
<p>Arrows 5 and 6 represent reversible binding of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e133" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e134" xlink:type="simple"/></inline-formula> to Axin, respectively. <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e135" xlink:type="simple"/></inline-formula> binds the GSK3 interaction domain (GID) of Axin <xref ref-type="bibr" rid="pcbi.1003217-Dajani1">[11]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Hedgepeth1">[28]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Frame1">[44]</xref>. <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e136" xlink:type="simple"/></inline-formula> binds a central region of Axin <xref ref-type="bibr" rid="pcbi.1003217-Sobrado1">[29]</xref>, which is distinct from the binding sites in Axin recognized by other binding partners. In the model, the binding of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e137" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e138" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e139" xlink:type="simple"/></inline-formula> to Axin is taken to be non-competitive and non-cooperative.</p>
<p>Arrows 7 and 8 represent phosphorylation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e140" xlink:type="simple"/></inline-formula> by Axin-bound <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e141" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e142" xlink:type="simple"/></inline-formula>, respectively. <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e143" xlink:type="simple"/></inline-formula> phosphorylation takes place in a processive manner <xref ref-type="bibr" rid="pcbi.1003217-Liu1">[12]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Wu1">[13]</xref>. <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e144" xlink:type="simple"/></inline-formula> first phosphorylates Ser-45 (labeled as S45 in <xref ref-type="fig" rid="pcbi-1003217-g001">Fig. 1</xref>), and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e145" xlink:type="simple"/></inline-formula> then phosphorylates Ser-33, Ser-37, and Thr-41. In the model, as a simplification, the latter three sites are lumped together (labeled as S33/S37 in <xref ref-type="fig" rid="pcbi-1003217-g002">Fig. 2</xref>). We model the phosphorylation reactions as processes with first-order kinetics that occur only when kinases and substrates are colocalized within a complex. In the model, phosphorylation at S45 occurs when <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e146" xlink:type="simple"/></inline-formula> is colocalized with Axin-associated <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e147" xlink:type="simple"/></inline-formula>. Phosphorylation at S33/S37 occurs when <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e148" xlink:type="simple"/></inline-formula> is phosphorylated at S45 and colocalized with Axin-associated <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e149" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003217-Liu1">[12]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Wu1">[13]</xref>. We do not consider phosphorylation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e150" xlink:type="simple"/></inline-formula> outside the context of the destruction complex.</p>
<p>Arrows 9 and 10 represent phosphorylation of APC 20-aa repeats by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e151" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e152" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003217-Ha1">[30]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Rubinfeld2">[45]</xref>. Both <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e153" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e154" xlink:type="simple"/></inline-formula> are required for phosphorylation of APC <xref ref-type="bibr" rid="pcbi.1003217-Ha1">[30]</xref>. In <xref ref-type="fig" rid="pcbi-1003217-g002">Fig. 2</xref>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e155" xlink:type="simple"/></inline-formula> is shown for illustration purposes only. In the model, we implicitly consider <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e156" xlink:type="simple"/></inline-formula> because it is not known which protein is responsible for colocalizing <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e157" xlink:type="simple"/></inline-formula> with APC. Phosphorylation of APC is taken to occur through a process with first-order kinetics when APC and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e158" xlink:type="simple"/></inline-formula> are colocalized via Axin. Thus, we assume that <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e159" xlink:type="simple"/></inline-formula> is colocalized with APC in proportion to the extent to which <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e160" xlink:type="simple"/></inline-formula> is colocalized with APC via Axin. This assumption is equivalent to assuming that <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e161" xlink:type="simple"/></inline-formula> associates non-competitively with Axin (or directly with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e162" xlink:type="simple"/></inline-formula>).</p>
<p>We model dephosphorylation reactions as first-order processes (without explicit consideration of phosphatases). We allow dephosphorylation to occur if a site is exposed, i.e., not occupied and shielded by a binding partner. In the model, both phosphorylation sites of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e163" xlink:type="simple"/></inline-formula> (i.e., S45 and S33/S37) are dephosphorylated according to the same rate law. In other words, the same first-order dephosphorylation rate constant is used for both sites. We allow the 20-aa repeats in APC to be dephosphorylated only if APC is in complex with Axin because Axin recruits PP2A, a phosphatase that mediates dephosphorylation of APC <xref ref-type="bibr" rid="pcbi.1003217-Ikeda1">[46]</xref>.</p>
<p>An important feature of the model is intracomplex binding of APC, Axin, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e164" xlink:type="simple"/></inline-formula>. In <xref ref-type="fig" rid="pcbi-1003217-g002">Fig. 2</xref>, Arrows 1–4 each represents two distinct types of binding reactions: intermolecular binding, and intracomplex binding. The former type of binding reaction occurs when the reacting sites are freely diffusing, i.e., not tethered. The latter type of binding reaction occurs when the reacting sites are already in a complex together, i.e., tethered and co-confined to a small subvolume of the cytoplasm. An intracomplex reaction can be marked by a high apparent affinity because of the high local concentrations of the tethered binding partners <xref ref-type="bibr" rid="pcbi.1003217-Crothers1">[47]</xref>. In the model, these reactions lead to complex stabilization. We account for the high local concentration effect on an intracomplex reaction by multiplying the corresponding forward rate constant by an enhancement factor <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e165" xlink:type="simple"/></inline-formula>. For instance, if <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e166" xlink:type="simple"/></inline-formula> and APC are already connected via Axin, then the effective forward rate constant for the reaction represented by Arrow 1 would be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e167" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e168" xlink:type="simple"/></inline-formula> is the intrinsic forward rate constant when the proteins are not tethered together.</p>
<p>It should be noted that in the model <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e169" xlink:type="simple"/></inline-formula> and APC can form a binary complex held together by two-point attachment i.e., <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e170" xlink:type="simple"/></inline-formula> and APC can be held together through simultaneous interaction between <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e171" xlink:type="simple"/></inline-formula> ARM repeats 3 and 4 and APC 20-aa repeats (Arrow 1) and interaction between <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e172" xlink:type="simple"/></inline-formula> ARM repeats 5–9 and APC 15-aa repeats (Arrow 2). The intracomplex reactions between APC and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e173" xlink:type="simple"/></inline-formula> are allowed to occur outside the context of a completely assembled destruction complex.</p>
<p>In the model, except for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e174" xlink:type="simple"/></inline-formula>, the total concentrations of signaling proteins are taken to be conserved (i.e., constant). <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e175" xlink:type="simple"/></inline-formula> is produced in a process with zeroth-order kinetics and degraded in either a slow or fast process with first-order kinetics. When S33/S37 is not phosphorylated, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e176" xlink:type="simple"/></inline-formula> is degraded at a slow rate, regardless of its bound state. When S33/S37 is phosphorylated, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e177" xlink:type="simple"/></inline-formula> is degraded at a fast rate, again regardless of its bound state. Thus, we allow <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e178" xlink:type="simple"/></inline-formula> to be degraded, through a slow or fast process, independently of whether it is free or bound. We assume that <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e179" xlink:type="simple"/></inline-formula> releases any binding partner(s) upon degradation.</p>
<p>The model has 27 independent parameters, including five protein concentrations and 14 binding constants (<xref ref-type="table" rid="pcbi-1003217-t001">Table 1</xref>). Parameter values were specified as described in <xref ref-type="sec" rid="s4">Materials and Methods</xref>. A local sensitivity analysis indicates that model behavior is not particularly sensitive to any individual parameter value (<xref ref-type="supplementary-material" rid="pcbi.1003217.s003">Table S1</xref>).</p>
<table-wrap id="pcbi-1003217-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003217.t001</object-id><label>Table 1</label><caption>
<title>Model parameter <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e180" xlink:type="simple"/></inline-formula><xref ref-type="table-fn" rid="nt101">1</xref>.</title>
</caption><alternatives><graphic id="pcbi-1003217-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003217.t001" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Parameters</td>
<td align="left" rowspan="1" colspan="1">Comments</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>BCAT<sub>tot</sub></italic> = 35 nM (1.1×10<xref ref-type="table-fn" rid="nt104">4</xref> copies/cell)</td>
<td align="left" rowspan="1" colspan="1"><italic>β</italic>–catenin concentration <xref ref-type="bibr" rid="pcbi.1003217-Lee1">[53]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Tan1">[59]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>APC<sub>tot</sub></italic> = 100 nM (3.2×10<xref ref-type="table-fn" rid="nt104">4</xref> copies/cell)</td>
<td align="left" rowspan="1" colspan="1">APC concentration <xref ref-type="bibr" rid="pcbi.1003217-Lee1">[53]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Tan1">[59]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>AXIN<sub>tot</sub></italic> = 10 nM (3.2×10<xref ref-type="table-fn" rid="nt103">3</xref> copies/cell)</td>
<td align="left" rowspan="1" colspan="1">Axin concentration <xref ref-type="bibr" rid="pcbi.1003217-Tan1">[59]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>GSK<sub>tot</sub></italic> = 100 nM (3.2×10<xref ref-type="table-fn" rid="nt104">4</xref> copies/cell)</td>
<td align="left" rowspan="1" colspan="1">GSK–3<italic>β</italic> concentration <xref ref-type="bibr" rid="pcbi.1003217-Lee1">[53]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Tan1">[59]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>CKl1α<sub>tot</sub></italic> = 100 nM (3.2×10<xref ref-type="table-fn" rid="nt104">4</xref>copies/cell)</td>
<td align="left" rowspan="1" colspan="1">CK1<italic>α</italic> concentration (assumed)</td>
</tr>
<tr>
<td colspan="2" align="left" rowspan="1"><italic>β</italic>–catenin ARM repeats 5–9 binding to the APC 15-aa repeat region</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>K<sub>D</sub></italic><sub>1,<italic>bap</italic></sub> = 273 nM</td>
<td align="left" rowspan="1" colspan="1">Equilibrium dissociation constant <xref ref-type="bibr" rid="pcbi.1003217-Kishida1">[43]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e181" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Dissociation rate constant<xref ref-type="table-fn" rid="nt102">2</xref></td>
</tr>
<tr>
<td colspan="2" align="left" rowspan="1"><italic>β</italic>–catenin ARM repeats 3 and 4 binding to the phosphorylated APC 20-aa repeat</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e182" xlink:type="simple"/></inline-formula> nM</td>
<td align="left" rowspan="1" colspan="1">Equilibrium dissociation constant <xref ref-type="bibr" rid="pcbi.1003217-Liu2">[25]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e183" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Dissociation rate constant<xref ref-type="table-fn" rid="nt102">2</xref></td>
</tr>
<tr>
<td colspan="2" align="left" rowspan="1"><italic>β</italic>–catenin ARM repeats 3 and 4 binding to the phosphorylated APC1338 20-aa repeat</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e184" xlink:type="simple"/></inline-formula> nM</td>
<td align="left" rowspan="1" colspan="1">Equilibrium dissociation constant <xref ref-type="bibr" rid="pcbi.1003217-Liu2">[25]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e185" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Dissociation rate constant<xref ref-type="table-fn" rid="nt102">2</xref></td>
</tr>
<tr>
<td colspan="2" align="left" rowspan="1"><italic>β</italic>–catenin ARM repeats 3 and 4 binding to Axin</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e186" xlink:type="simple"/></inline-formula> nM</td>
<td align="left" rowspan="1" colspan="1">Equilibrium dissociation constant <xref ref-type="bibr" rid="pcbi.1003217-Kishida1">[43]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e187" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Dissociation rate constant<xref ref-type="table-fn" rid="nt102">2</xref></td>
</tr>
<tr>
<td colspan="2" align="left" rowspan="1">Axin binding to the APC SAMP repeats</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e188" xlink:type="simple"/></inline-formula> nM</td>
<td align="left" rowspan="1" colspan="1">Equilibrium dissociation constant (assumed)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e189" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Dissociation rate constant<xref ref-type="table-fn" rid="nt102">2</xref></td>
</tr>
<tr>
<td colspan="2" align="left" rowspan="1">GSK–3<italic>β</italic> binding to Axin</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e190" xlink:type="simple"/></inline-formula> nM</td>
<td align="left" rowspan="1" colspan="1">Equilibrium dissociation constant <xref ref-type="bibr" rid="pcbi.1003217-Ikeda2">[68]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e191" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Dissociation rate constant<xref ref-type="table-fn" rid="nt102">2</xref></td>
</tr>
<tr>
<td colspan="2" align="left" rowspan="1">CK1<italic>α</italic> binding to Axin</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e192" xlink:type="simple"/></inline-formula> nM</td>
<td align="left" rowspan="1" colspan="1">Equilibrium dissociation constant (assumed)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e193" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Dissociation rate constant<xref ref-type="table-fn" rid="nt102">2</xref></td>
</tr>
<tr>
<td colspan="2" align="left" rowspan="1"><italic>β</italic>–catenin phosphorylation and dephosphorylation (at both S33/S37 and S45 sites)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e194" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><italic>β</italic>–catenin phosphorylation rate constant</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e195" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><italic>β</italic>–catenin dephosphorylation rate constant<xref ref-type="table-fn" rid="nt103">3</xref></td>
</tr>
<tr>
<td colspan="2" align="left" rowspan="1">APC/APC1338 phosphorylation and dephosphorylation at the 20-aa repeat region (site 1 or 3)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e196" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">APC phosphorylation rate constant<xref ref-type="table-fn" rid="nt104">4</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e197" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">APC dephosphorylation rate constant<xref ref-type="table-fn" rid="nt104">4</xref></td>
</tr>
<tr>
<td colspan="2" align="left" rowspan="1"><italic>β</italic>–catenin synthesis and degradation</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e198" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Slow degradation rate constant<xref ref-type="table-fn" rid="nt104">4</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e199" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Fast degradation rate constant<xref ref-type="table-fn" rid="nt104">4</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e200" xlink:type="simple"/></inline-formula> (4.0 molecules/s)</td>
<td align="left" rowspan="1" colspan="1">Synthesis rate constant<xref ref-type="table-fn" rid="nt104">4</xref></td>
</tr>
<tr>
<td colspan="2" align="left" rowspan="1">Enhancement factor</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>χ</italic> = 10<xref ref-type="table-fn" rid="nt104">4</xref> nM</td>
<td align="left" rowspan="1" colspan="1">Enhancement factor for intracomplex binding<xref ref-type="table-fn" rid="nt104">4</xref></td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt101"><label>1</label><p>Unit conversions are based on a cell cytoplasmic volume of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e201" xlink:type="simple"/></inline-formula> L <xref ref-type="bibr" rid="pcbi.1003217-Tan1">[59]</xref>.</p></fn><fn id="nt102"><label>2</label><p>For each binding reaction, the association rate constant (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e202" xlink:type="simple"/></inline-formula>) is assumed to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e203" xlink:type="simple"/></inline-formula>.</p></fn><fn id="nt103"><label>3</label><p>The half-life <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e204" xlink:type="simple"/></inline-formula> of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e205" xlink:type="simple"/></inline-formula> phosphorylation is approximately 10 min <xref ref-type="bibr" rid="pcbi.1003217-Sadot1">[74]</xref>.</p></fn><fn id="nt104"><label>4</label><p>The selected parameter values allow the model to reproduce a number of experimental observations, including 1) the steady-state <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e206" xlink:type="simple"/></inline-formula> level, 2) the half-lives of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e207" xlink:type="simple"/></inline-formula> and S33/S37-mutated <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e208" xlink:type="simple"/></inline-formula> (<xref ref-type="supplementary-material" rid="pcbi.1003217.s001">Fig. S1</xref>), and 3) the kinetics of dephosphorylation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e209" xlink:type="simple"/></inline-formula> at S33/S37 and S45 upon treatment with LiCl (<xref ref-type="supplementary-material" rid="pcbi.1003217.s002">Fig. S2</xref>).</p></fn><fn id="nt105"><label/><p>See <xref ref-type="sec" rid="s4">Materials and Methods</xref> for more details.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2b">
<title>Effects of APC mutation on <italic>β</italic>–catenin expression</title>
<p>Using the estimated parameter values summarized in <xref ref-type="table" rid="pcbi-1003217-t001">Table 1</xref> (see <xref ref-type="sec" rid="s4">Materials and Methods</xref>), which were selected in part to allow the model to reproduce certain system behaviors (<xref ref-type="supplementary-material" rid="pcbi.1003217.s001">Figs. S1</xref> and <xref ref-type="supplementary-material" rid="pcbi.1003217.s002">S2</xref>), we tested whether the model is able to predict the effects of transfection of SW480 cells with different truncated forms of APC. Munemitsu et al. <xref ref-type="bibr" rid="pcbi.1003217-Munemitsu1">[31]</xref> systematically transfected SW480 cells with various forms of APC. These experiments were designed to understand the effects of deletion of different functional components of APC on <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e210" xlink:type="simple"/></inline-formula> levels in SW480 cells, which almost exclusively express APC1338 instead of the full-length protein <xref ref-type="bibr" rid="pcbi.1003217-Munemitsu1">[31]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Smith1">[48]</xref>.</p>
<p>Munemitsu et al. <xref ref-type="bibr" rid="pcbi.1003217-Munemitsu1">[31]</xref> transfected SW480 cells with full-length APC or one of 11 different truncated forms of APC (illustrated in <xref ref-type="fig" rid="pcbi-1003217-g003">Fig. 3</xref>). In our model, full-length APC and the 11 truncated forms of the protein can be grouped into six distinctive classes, Classes A–F (<xref ref-type="fig" rid="pcbi-1003217-g003">Fig. 3</xref>). The proteins in each class are functionally equivalent based on the components and interactions of APC included in the model (<xref ref-type="fig" rid="pcbi-1003217-g002">Fig. 2</xref>). For example, Munemitsu et al. <xref ref-type="bibr" rid="pcbi.1003217-Munemitsu1">[31]</xref> considered three forms of APC each containing the following components: 1) a partial or complete set of the 15-aa repeats, 2) all of the 20-aa repeats, and 3) the SAMP repeats of APC. These are the functional sites that we consider to be included in full-length APC (<xref ref-type="fig" rid="pcbi-1003217-g002">Fig. 2</xref>). Therefore, we will use APC-A to represent all three proteins, as we take these forms of APC to be functionally equivalent. Similarly, we will use APC-B to represent two other proteins, which both contain the 15-aa repeats and only the first 20-aa repeat. We take these two forms to be equivalent to APC1338, the truncated protein in SW480 cells. Henceforth, we will use APC-A, APC-B, APC-C, APC-D, APC-E and APC-F to refer to the proteins in Classes A (e.g., full-length APC), B (e.g., APC1338), C, D, E and F (<xref ref-type="fig" rid="pcbi-1003217-g003">Fig. 3</xref>).</p>
<fig id="pcbi-1003217-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003217.g003</object-id><label>Figure 3</label><caption>
<title>Summary of APC constructs considered in simulated transfections and in the experimental study of Munemitsu et al. <xref ref-type="bibr" rid="pcbi.1003217-Munemitsu1">[31]</xref>.</title>
<p>The 12 constructs used by Munemitsu et al. <xref ref-type="bibr" rid="pcbi.1003217-Munemitsu1">[31]</xref> are divided into six classes based on their structures. Proteins within the same class are functionally equivalent according to our model. A representative of Class A (APC-A) contains all three protein binding sites considered in the model for full-length APC. This class is regarded as equivalent to full-length APC. A representative of Class B (APC-B) contains 15-aa repeats and the first 20-aa repeat. This class is regarded as equivalent to APC1338, the truncated form of APC found in SW480 cells. A representative of Class C (APC-C) corresponds to a fragment that contains only the 15-aa repeats. A representative of Class D (APC-D) corresponds to a fragment that contains only the first 20-aa repeat. A representative of Class E (APC-E) corresponds to a fragment that contains the 20-aa and SAMP repeats. A representative of Class F (APC-F) corresponds to a nonfunctional fragment that contains none of the three APC sites included in the model.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003217.g003" position="float" xlink:type="simple"/></fig>
<p>Using the model, we investigated the effects of transfection of SW480 cells with APC-A through APC-F. In the model, the endogeneous concentration of APC1338 in an SW480 cell is set at 100 nM. Similarly, the endogeneous concentration of full-length APC in a normal cell is set at 100 nM (<xref ref-type="table" rid="pcbi-1003217-t001">Table 1</xref>). Because APC1338 does not contain the third 20-aa repeat, nor SAMP repeats, Axin interactions associated with these sites (<xref ref-type="fig" rid="pcbi-1003217-g002">Fig. 2</xref>) are absent in an SW480 cell. In contrast, in a normal cell, all interactions considered in the model are active, except for the low-affinity interaction between APC and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e211" xlink:type="simple"/></inline-formula> involving the phosphorylated first 20-aa repeat of APC and ARM repeats 3 and 4 of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e212" xlink:type="simple"/></inline-formula>. This low-affinity interaction is omitted when considering a normal cell as a simplification (see <xref ref-type="sec" rid="s4">Materials and Methods</xref>). In the model, when a representative of one of the six classes of APC is introduced into an SW480 cell, any novel interactions associated with the functional components of the transfected protein become active. For example, when APC-A is introduced, interactions associated with the third 20-aa repeat and the SAMP repeats (<xref ref-type="fig" rid="pcbi-1003217-g002">Fig. 2</xref>) become active. These interactions are normally missing in an SW480 cell. We assume that simulated transfections each introduce 100 nM of new protein into a cell. Thus, simulated transfection of SW480 with a particular form of APC implies that the cell contains 100 nM of a protein belonging to that form in addition to the 100 nM of the endogeneous form of APC (APC1338). (We systematically investigate how behavior depends on the amount of transfected protein below.)</p>
<p>In <xref ref-type="fig" rid="pcbi-1003217-g004">Fig. 4</xref>, we compare the model-predicted changes in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e213" xlink:type="simple"/></inline-formula> levels in SW480 cells after simulated transfection of different forms of APC against the findings of Munemitsu et al. <xref ref-type="bibr" rid="pcbi.1003217-Munemitsu1">[31]</xref> (<xref ref-type="fig" rid="pcbi-1003217-g004">Fig. 4</xref>). The model is able to recapitulate the qualitative increase or decrease in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e214" xlink:type="simple"/></inline-formula> level observed after transfection of each class of protein. Consistent with the findings of Munemitsu et al. <xref ref-type="bibr" rid="pcbi.1003217-Munemitsu1">[31]</xref>, the model predicts that only transfection of APC-A and APC-E leads to a decrease in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e215" xlink:type="simple"/></inline-formula> level, whereas the other four classes of APC have the opposite or no effect on <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e216" xlink:type="simple"/></inline-formula> level (<xref ref-type="fig" rid="pcbi-1003217-g004">Fig. 4</xref>) <xref ref-type="bibr" rid="pcbi.1003217-Munemitsu1">[31]</xref>. It should be noted that the results in <xref ref-type="fig" rid="pcbi-1003217-g004">Fig. 4</xref> were obtained without adjustment or fitting of parameter values.</p>
<fig id="pcbi-1003217-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003217.g004</object-id><label>Figure 4</label><caption>
<title>Comparison of simulated and observed effects of transfection of SW480 cells with APC constructs.</title>
<p>Relative <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e217" xlink:type="simple"/></inline-formula> levels in SW480 cells in response to transfection with the APC constructs of <xref ref-type="fig" rid="pcbi-1003217-g003">Fig. 3</xref> are shown. The gray bars, which correspond to the left <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e218" xlink:type="simple"/></inline-formula>, represent experimental data from Munemitsu et al. <xref ref-type="bibr" rid="pcbi.1003217-Munemitsu1">[31]</xref>. The black bars, which correspond to the right <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e219" xlink:type="simple"/></inline-formula>, represent model predictions. The predicted concentrations (black bars) are each divided by the concentration of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e220" xlink:type="simple"/></inline-formula> in a normal cell (35 nM, <xref ref-type="table" rid="pcbi-1003217-t001">Table 1</xref>). For all APC constructs, the same transfection efficiency is assumed. We take a transfected cell to contain 100 nM of added protein. The predicted results therefore represent the effects of 100 nM of a construct in addition to 100 nM of endogeneous APC1338. The simulation results shown here were obtained using BioNetGen input files provided in the Supporting Information: <xref ref-type="supplementary-material" rid="pcbi.1003217.s006">Text S3</xref> was used for the APC-B and APC-F cases, <xref ref-type="supplementary-material" rid="pcbi.1003217.s007">Text S4</xref> was used for the APC-A case, <xref ref-type="supplementary-material" rid="pcbi.1003217.s008">Text S5</xref> was used for the APC-C case, <xref ref-type="supplementary-material" rid="pcbi.1003217.s009">Text S6</xref> was used for the APC-D case, and <xref ref-type="supplementary-material" rid="pcbi.1003217.s010">Text S7</xref> was used for the APC-E case.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003217.g004" position="float" xlink:type="simple"/></fig></sec><sec id="s2c">
<title>Role of full-length APC in <italic>β</italic>–catenin degradation</title>
<p>The results of Munemitsu et al. <xref ref-type="bibr" rid="pcbi.1003217-Munemitsu1">[31]</xref> suggest that exogeneous full-length APC downregulates <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e221" xlink:type="simple"/></inline-formula> by promoting <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e222" xlink:type="simple"/></inline-formula> degradation in SW480 cells. Similar results for SW480 cells have been obtained in other studies <xref ref-type="bibr" rid="pcbi.1003217-Yang1">[33]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Faux1">[34]</xref>. However, transfection of different cell types have yielded different results <xref ref-type="bibr" rid="pcbi.1003217-Yang1">[33]</xref>. Using our model, we investigated whether overexpression of APC can generally be expected to increase the rate of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e223" xlink:type="simple"/></inline-formula> degradation in all cell types, or if the effect may be specific to SW480 cells only (<xref ref-type="fig" rid="pcbi-1003217-g005">Fig. 5</xref>).</p>
<fig id="pcbi-1003217-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003217.g005</object-id><label>Figure 5</label><caption>
<title>Concentration-dependent effects of full-length APC on <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e224" xlink:type="simple"/></inline-formula>.</title>
<p>(A) <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e225" xlink:type="simple"/></inline-formula> level in a normal cell is shown as a function of APC concentration. The <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e226" xlink:type="simple"/></inline-formula> represents the relative amount of APC introduced exogeneously with respect to the endogeneously present 100 nM of full-length APC in a normal cell. The <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e227" xlink:type="simple"/></inline-formula> represents the level of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e228" xlink:type="simple"/></inline-formula> relative to its nominal level in a normal cell (<xref ref-type="table" rid="pcbi-1003217-t001">Table 1</xref>). (B) <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e229" xlink:type="simple"/></inline-formula> level in an SW480 cell is shown as a function of APC concentration. The <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e230" xlink:type="simple"/></inline-formula> represents the amount of APC introduced exogeneously relative to the endogeneously present 100 nM of APC1338 in an SW480 cell. The <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e231" xlink:type="simple"/></inline-formula> represents the level of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e232" xlink:type="simple"/></inline-formula> relative to its nominal level in a normal cell, as in panel A. The simulation results shown here were obtained using BioNetGen input files provided in the Supporting Information: <xref ref-type="supplementary-material" rid="pcbi.1003217.s005">Text S2</xref> was used for panel A and <xref ref-type="supplementary-material" rid="pcbi.1003217.s007">Text S4</xref> was used for panel B.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003217.g005" position="float" xlink:type="simple"/></fig>
<p><xref ref-type="fig" rid="pcbi-1003217-g005">Fig. 5A</xref> shows the model-predicted <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e233" xlink:type="simple"/></inline-formula> level in a normal cell as a function of APC level. A normal cell in the model is taken to have endogeneous full-length APC at a cytosolic concentration of 100 nM (<xref ref-type="table" rid="pcbi-1003217-t001">Table 1</xref>). <xref ref-type="fig" rid="pcbi-1003217-g005">Fig. 5A</xref> illustrates the predicted effects of added APC. <xref ref-type="fig" rid="pcbi-1003217-g005">Fig. 5A</xref> shows that increased abundance of APC does not promote <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e234" xlink:type="simple"/></inline-formula> degradation, rather it has a concentration-dependent positive effect on <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e235" xlink:type="simple"/></inline-formula> level in normal cells, in contrast to the effect in SW480 cells (<xref ref-type="fig" rid="pcbi-1003217-g004">Fig. 4</xref>). The effects of exogenous full-length APC at different concentrations in SW480 cells are considered in <xref ref-type="fig" rid="pcbi-1003217-g005">Fig. 5B</xref>, which shows the model-predicted <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e236" xlink:type="simple"/></inline-formula> level in SW480 cells as a function of full-length APC level. An SW480 cell is taken to have endogeneous APC1338 at a cytosolic concentration of 100 nM (<xref ref-type="table" rid="pcbi-1003217-t001">Table 1</xref>). The predicted effect of added full-length APC is a significant decrease in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e237" xlink:type="simple"/></inline-formula> level in SW480 cells over a wide range of exogeneous full-length APC expression levels (<xref ref-type="fig" rid="pcbi-1003217-g005">Fig. 5B</xref>). This finding is consistent with the effects of transient expression of full-length APC in SW480 cells <xref ref-type="bibr" rid="pcbi.1003217-Munemitsu1">[31]</xref> and to some extent also with stable expression of full-length APC in SW480 cells <xref ref-type="bibr" rid="pcbi.1003217-Faux1">[34]</xref>.</p>
</sec><sec id="s2d">
<title>Concentration-dependent effects of truncated forms of APC in SW480 cells</title>
<p>In <xref ref-type="fig" rid="pcbi-1003217-g004">Fig. 4</xref>, we assumed a fixed amount (100 nM) of exogeneous expression for all six classes of APC. However, the results in <xref ref-type="fig" rid="pcbi-1003217-g004">Fig. 4</xref> could depend on APC concentration, as seen for APC-A (<xref ref-type="fig" rid="pcbi-1003217-g005">Fig. 5</xref>). Therefore, we investigated the predicted concentration-dependent effects of APC-B, -C, -D and -E on <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e238" xlink:type="simple"/></inline-formula> levels in SW480 cells (<xref ref-type="fig" rid="pcbi-1003217-g006">Fig. 6</xref>). For APC-A, such effects have already been discussed (<xref ref-type="fig" rid="pcbi-1003217-g005">Fig. 5B</xref>). We do not consider APC-F because in our model it represents a non-functional form of APC with no binding sites.</p>
<fig id="pcbi-1003217-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003217.g006</object-id><label>Figure 6</label><caption>
<title>Concentration-dependent effects of APC constructs in SW480 cells.</title>
<p>Predicted <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e239" xlink:type="simple"/></inline-formula> level is shown as a function of expression level for APC-B, -C, -D, and -E. In each panel, the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e240" xlink:type="simple"/></inline-formula> represents the amount of expression relative to the endogeneous level of APC1338 (100 nM). The <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e241" xlink:type="simple"/></inline-formula> represents the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e242" xlink:type="simple"/></inline-formula> level relative to the nominal level in a normal cell (35 nM, <xref ref-type="table" rid="pcbi-1003217-t001">Table 1</xref>). Thus, a value of 1 on the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e243" xlink:type="simple"/></inline-formula> corresponds to a concentration of 100 nM of transfected protein, and a value of 1 on the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e244" xlink:type="simple"/></inline-formula> corresponds to a concentration of 35 nM of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e245" xlink:type="simple"/></inline-formula>. The simulation results shown here were obtained using BioNetGen input files provided in the Supporting Information: <xref ref-type="supplementary-material" rid="pcbi.1003217.s006">Text S3</xref> was used for panel A, <xref ref-type="supplementary-material" rid="pcbi.1003217.s008">Text S5</xref> was used for panel B, <xref ref-type="supplementary-material" rid="pcbi.1003217.s009">Text S6</xref> was used for panel C, and <xref ref-type="supplementary-material" rid="pcbi.1003217.s010">Text S7</xref> was used for panel D.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003217.g006" position="float" xlink:type="simple"/></fig>
<p>The simulation results in <xref ref-type="fig" rid="pcbi-1003217-g006">Fig. 6</xref> illustrate the concentration-dependent effects of APC-B, -C, -D and -E. As seen in <xref ref-type="fig" rid="pcbi-1003217-g006">Fig. 6A</xref>, added APC-B (e.g., APC1338) increases <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e246" xlink:type="simple"/></inline-formula> level over the entire concentration range considered. The level of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e247" xlink:type="simple"/></inline-formula> doubles as the amount of exogeneous APC1338 approaches a 10-fold higher amount of endogeneous APC1338 (<xref ref-type="fig" rid="pcbi-1003217-g006">Fig. 6A</xref>). Unlike APC-B, the other three proteins do not increase <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e248" xlink:type="simple"/></inline-formula> level over the entire concentration range. APC-C reduces <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e249" xlink:type="simple"/></inline-formula> level at relatively high concentrations (<xref ref-type="fig" rid="pcbi-1003217-g006">Fig. 6B</xref>), APC-D does not alter <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e250" xlink:type="simple"/></inline-formula> level at any concentration (<xref ref-type="fig" rid="pcbi-1003217-g006">Fig. 6C</xref>), and APC-E reduces <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e251" xlink:type="simple"/></inline-formula> level over a range of intermediate concentrations in a manner similar to full-length APC (cf. <xref ref-type="fig" rid="pcbi-1003217-g006">Fig. 6D</xref> and <xref ref-type="fig" rid="pcbi-1003217-g005">Fig. 5B</xref>).</p>
<p>The only difference between APC-B and APC-C is that the former form of APC contains the first 20-aa repeat, whereas the latter form does not. This distinction leads to APC-B and APC-C having opposite effects on <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e252" xlink:type="simple"/></inline-formula> level in SW480 cells (cf. <xref ref-type="fig" rid="pcbi-1003217-g006">Figs. 6A and 6B</xref>). APC-D contains the first 20-aa repeat but no other functional components of APC that are able to interact with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e253" xlink:type="simple"/></inline-formula> or Axin. Therefore, APC-D cannot interact with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e254" xlink:type="simple"/></inline-formula> because of the consequent absence of phosphorylation of the 20-aa repeat. The 20-aa repeat in APC-D is never phosphorylated because the unphosphorylated protein is unable to interact with Axin. Thus, APC-D has no effect on <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e255" xlink:type="simple"/></inline-formula> level (<xref ref-type="fig" rid="pcbi-1003217-g006">Fig. 6C</xref>). APC-E entails all structural features of APC-B, but in addition it contains SAMP repeats, which mediate Axin binding (<xref ref-type="fig" rid="pcbi-1003217-g002">Fig. 2</xref>). Because of this distinctive feature, the model predicts that APC-E behaves differently from APC1338 and produces reduced <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e256" xlink:type="simple"/></inline-formula> levels at intermediate concentrations of APC-E similar to the predicted effects of full-length APC (<xref ref-type="fig" rid="pcbi-1003217-g005">Fig. 5B</xref>). These results indicate that the absence of SAMP repeats in APC1338 may have an important role in APC1338-mediated increases of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e257" xlink:type="simple"/></inline-formula> levels in cancer cells.</p>
</sec><sec id="s2e">
<title>Phosphorylation-dependent competition between APC1338 and Axin for binding to <italic>β</italic>–catenin</title>
<p>The analysis of <xref ref-type="fig" rid="pcbi-1003217-g006">Fig. 6</xref> indicated that APC-B (e.g., APC1338) and APC-C have opposite effects on <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e258" xlink:type="simple"/></inline-formula> level because APC-B contains a 20-aa repeat that APC-C does not. In <xref ref-type="fig" rid="pcbi-1003217-g007">Fig. 7</xref>, we analyze the effects of phosphorylation of the 20-aa repeat in APC-B on <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e259" xlink:type="simple"/></inline-formula> levels in SW480 cells. Recall that phosphorylation of the 20-aa repeat in APC is mediated by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e260" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e261" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003217-Ha1">[30]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Rubinfeld2">[45]</xref> and that phosphorylation of this site is necessary for direct interaction of APC with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e262" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003217-Xing1">[22]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Liu2">[25]</xref>.</p>
<fig id="pcbi-1003217-g007" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003217.g007</object-id><label>Figure 7</label><caption>
<title>APC1338 phosphorylation and its competition with Axin for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e263" xlink:type="simple"/></inline-formula>.</title>
<p>(A) <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e264" xlink:type="simple"/></inline-formula> level is shown at different levels of APC1338 phosphorylation. Phosphorylation of APC1338 at the first 20-aa repeat is modulated by changing the values of the phosphorylation and dephosphorylation rate constants <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e265" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e266" xlink:type="simple"/></inline-formula>. In the figure, the ratio, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e267" xlink:type="simple"/></inline-formula> corresponds to the default values of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e268" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e269" xlink:type="simple"/></inline-formula> in the model, which are taken to be the same (<xref ref-type="table" rid="pcbi-1003217-t001">Table 1</xref>). The case where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e270" xlink:type="simple"/></inline-formula> represents an extreme, where the 20-aa repeat always remains phosphorylated. The case where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e271" xlink:type="simple"/></inline-formula> represents the opposite extreme, where APC1338 never becomes phosphorylated. (B) Competition effects on <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e272" xlink:type="simple"/></inline-formula> binding arising from APC1338 phosphorylation. The <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e273" xlink:type="simple"/></inline-formula> represents the fraction of Axin in complex with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e274" xlink:type="simple"/></inline-formula>. The patterns of the lines represent different phosphorylation and dephosphorylation rate constants, as labeled in panel A. The simulation results shown here were obtained using <xref ref-type="supplementary-material" rid="pcbi.1003217.s006">Text S3</xref>, a BioNetGen input file provided in the Supporting Information.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003217.g007" position="float" xlink:type="simple"/></fig>
<p>The simulation results shown in <xref ref-type="fig" rid="pcbi-1003217-g007">Fig. 7A</xref> indicate that phosphorylation of the 20-aa repeat is needed for APC-B/APC1338-mediated stabilization of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e275" xlink:type="simple"/></inline-formula>. In the figure, the solid line corresponds to default rate constants for phosphorylation and dephosphorylation of APC in the model (<xref ref-type="table" rid="pcbi-1003217-t001">Table 1</xref>). For these parameter values, the 20-aa repeat is nearly always phosphorylated. This case can be viewed as the extreme opposite of the case where the 20-aa repeat is deleted and therefore never present in phosphorylated form. When the 20-aa repeat is deleted, APC-B becomes equivalent to APC-C and downregulates <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e276" xlink:type="simple"/></inline-formula> in a similar manner (cf. <xref ref-type="fig" rid="pcbi-1003217-g007">Fig. 7A</xref> and <xref ref-type="fig" rid="pcbi-1003217-g006">Fig. 6C</xref>).</p>
<p>Phosphorylated APC1338 binds to ARM repeats 3 and 4 in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e277" xlink:type="simple"/></inline-formula>, which is also a binding site for Axin (<xref ref-type="fig" rid="pcbi-1003217-g002">Fig. 2</xref>). Thus, phosphorylated APC1338 competes with Axin for binding to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e278" xlink:type="simple"/></inline-formula> and can inhibit phosphorylation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e279" xlink:type="simple"/></inline-formula> by sequestering <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e280" xlink:type="simple"/></inline-formula> away from Axin-associated kinases. <xref ref-type="fig" rid="pcbi-1003217-g007">Fig. 7B</xref> illustrates the predicted effect of APC1338 phosphorylation on association of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e281" xlink:type="simple"/></inline-formula> and Axin. The simulation results of <xref ref-type="fig" rid="pcbi-1003217-g007">Fig. 7B</xref> show that phosphorylation of APC1338 inhibits interaction of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e282" xlink:type="simple"/></inline-formula> with Axin.</p>
</sec><sec id="s2f">
<title>Mechanism of <italic>β</italic>–catenin upregulation by APC1338</title>
<p>The results of <xref ref-type="fig" rid="pcbi-1003217-g007">Fig. 7</xref> suggest that competition between APC1338 and Axin for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e283" xlink:type="simple"/></inline-formula> binding upregulates <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e284" xlink:type="simple"/></inline-formula> levels in SW480 cells. These results however do not explain how APC1338 and APC regulate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e285" xlink:type="simple"/></inline-formula> differentially. Differential regulation is somewhat paradoxical because both proteins have phosphorylation sites in the 20-aa repeat region, which mediates <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e286" xlink:type="simple"/></inline-formula> binding. The distinction between APC and APC1338 can be attributed to the absence of SAMP repeats in APC1338, as explained fully below. In short, APC1338 sequesters <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e287" xlink:type="simple"/></inline-formula> away from Axin, whereas APC fails to do so (<xref ref-type="fig" rid="pcbi-1003217-g008">Fig. 8</xref>). The sequestration effect arises because APC1338, lacking SAMP repeats, cannot mediate indirect association of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e288" xlink:type="simple"/></inline-formula> with Axin. We note that the bell-shaped curve in <xref ref-type="fig" rid="pcbi-1003217-g008">Fig. 8B</xref> represents a characteristic scaffold effect <xref ref-type="bibr" rid="pcbi.1003217-Yang2">[49]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Douglass1">[50]</xref>. Here, the scaffold is APC and the scaffold ligands are Axin and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e289" xlink:type="simple"/></inline-formula>.</p>
<fig id="pcbi-1003217-g008" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003217.g008</object-id><label>Figure 8</label><caption>
<title>Sequestration of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e290" xlink:type="simple"/></inline-formula> away from Axin by APC1338.</title>
<p>(A) Predicted amount of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e291" xlink:type="simple"/></inline-formula> associated either directly or indirectly with Axin is shown as a function of APC1338 concentration in the background of an SW480 cell. The horizontal axis indicates the amount of APC1338 divided by the nominal amount of APC1338 in an SW480 cell (100 nM). The vertical axis indicates the amount of Axin-associated <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e292" xlink:type="simple"/></inline-formula> divided by the total amount of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e293" xlink:type="simple"/></inline-formula> at steady state, which is a function of APC1338 concentration. (B) Predicted amount of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e294" xlink:type="simple"/></inline-formula> associated either directly or indirectly with Axin is shown as a function of full-length APC concentration in the background of a normal cell. The horizontal axis indicates the amount of full-length APC divided by the nominal amount of full-length APC in a normal cell (100 nM). The vertical axis indicates the amount of Axin-associated <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e295" xlink:type="simple"/></inline-formula> divided by the total amount of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e296" xlink:type="simple"/></inline-formula> at steady state, which is a function of full-length APC concentration. (C) Predicted amount of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e297" xlink:type="simple"/></inline-formula> associated directly with APC1338 as a function of relative APC1338 concentration. (D) Predicted amount of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e298" xlink:type="simple"/></inline-formula> associated directly with full-length APC as a function of relative full-length APC concentration. All results shown were obtained using the parameter values of <xref ref-type="table" rid="pcbi-1003217-t001">Table 1</xref>, except as indicated. The following BioNetGen input files were used to obtain simulation results: <xref ref-type="supplementary-material" rid="pcbi.1003217.s006">Text S3</xref> was used for panels A and C and <xref ref-type="supplementary-material" rid="pcbi.1003217.s005">Text S2</xref> was used for panels B and D.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003217.g008" position="float" xlink:type="simple"/></fig>
<p>In normal cells, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e299" xlink:type="simple"/></inline-formula> can associate with Axin in two ways: 1) direct binding via ARM repeats 3 and 4 in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e300" xlink:type="simple"/></inline-formula> (Arrow 3; <xref ref-type="fig" rid="pcbi-1003217-g002">Fig. 2</xref>), and 2) indirect binding via APC, with APC acting as a linker between <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e301" xlink:type="simple"/></inline-formula> and Axin (Arrows 2 and 4; <xref ref-type="fig" rid="pcbi-1003217-g002">Fig. 2</xref>). As in an SW480 cell, the direct interaction in a normal cell is also inhibited by phosphorylation of the 20-aa repeat region in APC because of competition between phosphorylated APC and Axin for binding to ARM repeats 3 and 4 in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e302" xlink:type="simple"/></inline-formula>. Nonetheless, in a normal cell, the indirect interaction still enables <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e303" xlink:type="simple"/></inline-formula> to colocalize with Axin via APC <xref ref-type="bibr" rid="pcbi.1003217-Ha1">[30]</xref>, thus allowing phosphorylation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e304" xlink:type="simple"/></inline-formula> to occur via Axin-associated kinases, which leads to degradation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e305" xlink:type="simple"/></inline-formula>. In contrast, in SW480 cells, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e306" xlink:type="simple"/></inline-formula> can associate with Axin only through direct interaction. The indirect interaction does not occur because APC1338 lacks the SAMP repeats necessary for Axin binding. Thus, in SW480 cells, APC1338 phosphorylation effectively blocks <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e307" xlink:type="simple"/></inline-formula> association with Axin, leading to less degradation. A corollary of this finding is that increased expression of Axin would be expected to increase the degradation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e308" xlink:type="simple"/></inline-formula>, which has been observed <xref ref-type="bibr" rid="pcbi.1003217-Faux2">[36]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Behrens2">[51]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Hart1">[52]</xref>.</p>
</sec><sec id="s2g">
<title>Effect of stability of the core destruction complex on <italic>β</italic>–catenin level</title>
<p>The stability of the destruction complex can be perturbed (decreased) by preventing APC, Axin, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e309" xlink:type="simple"/></inline-formula> from forming a closed/cyclic ternary complex. The cyclic complex, which we assume can form in normal cells, cannot form in SW480 cells as a result of APC truncation. Formation of the cyclic ternary complex can be prevented not only by truncation of APC but also by other mutations. Any mutation affecting one of the three protein-protein interfaces of the ternary complex would prevent closure of the cyclic structure. Using our model, we simulated inhibition of formation of the cyclic structure by systematically blocking each of the three protein-protein interfaces of the closed/cyclic ternary complex, and we determined the resulting effect on <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e310" xlink:type="simple"/></inline-formula> level. As seen in <xref ref-type="fig" rid="pcbi-1003217-g009">Fig. 9</xref>, blocking the contact between APC and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e311" xlink:type="simple"/></inline-formula> or <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e312" xlink:type="simple"/></inline-formula> and Axin did not change <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e313" xlink:type="simple"/></inline-formula> level, indicating that the cyclic structure is unimportant for regulation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e314" xlink:type="simple"/></inline-formula> level. Only blocking of the interface between APC and Axin (by removal of SAMP repeats) is predicted to upregulate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e315" xlink:type="simple"/></inline-formula> level. However, as established above, this behavior arises for reasons other than destablilization of the cyclic ternary complex of APC, Axin, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e316" xlink:type="simple"/></inline-formula>. Thus, our model indicates that destabilization of this complex (through ablation of cyclization) is not an important effect of APC truncation.</p>
<fig id="pcbi-1003217-g009" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003217.g009</object-id><label>Figure 9</label><caption>
<title>Effects of simulated perturbations of the putative closed/cyclic core destruction complex.</title>
<p>Three cases are considered, as indicated in the descriptions of Text S8, S9, S10 (Supporting Information). Each of the three protein-protein interfaces, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e317" xlink:type="simple"/></inline-formula> (<xref ref-type="supplementary-material" rid="pcbi.1003217.s011">Text S8</xref>), <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e318" xlink:type="simple"/></inline-formula> (<xref ref-type="supplementary-material" rid="pcbi.1003217.s012">Text S9</xref>), and APC-Axin (<xref ref-type="supplementary-material" rid="pcbi.1003217.s013">Text S10</xref>), is ablated such that a closed/cylic structure cannot form. The relative <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e319" xlink:type="simple"/></inline-formula> level in each case is compared with the nominal <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e320" xlink:type="simple"/></inline-formula> level in a normal cell.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003217.g009" position="float" xlink:type="simple"/></fig></sec></sec><sec id="s3">
<title>Discussion</title>
<p>In this study, we have modeled <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e321" xlink:type="simple"/></inline-formula> regulation by the destruction complex in normal and colorectal cancer cells, which express full-length and truncated APC, respectively. Our model, illustrated in <xref ref-type="fig" rid="pcbi-1003217-g001">Figs. 1</xref> and <xref ref-type="fig" rid="pcbi-1003217-g002">2</xref>, incorporates site-specific mechanistic details about the destruction complex, which comprises a number of signaling proteins. In colorectal cancer cells (e.g., SW480 cells), the interactions of these proteins are altered by truncation of APC. We have used our model to study the function of APC and the effects of its truncation on <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e322" xlink:type="simple"/></inline-formula> phosphorylation and phosphorylation-dependent degradation. We caution that our results pertain to only the function of APC within an idealized destruction complex and furthermore that we considered the interactions of particular (multifunctional) proteins in isolation from most of their binding partners. Thus, within the context of a cell, the functional effects of APC or truncated APC overexpression could potentially be very different from what our model predicts. Nevertheless, the model is qualitatively consistent with the observed effects of transient expression of various recombinant forms of APC in SW480 cells <xref ref-type="bibr" rid="pcbi.1003217-Munemitsu1">[31]</xref> (<xref ref-type="fig" rid="pcbi-1003217-g004">Fig. 4</xref>). Stronger, less ambiguous tests of model predictions in the future would ideally be performed using an <italic>in vitro</italic> reconstituted or cell-free system <xref ref-type="bibr" rid="pcbi.1003217-Lee1">[53]</xref> to eliminate the uncertainties and complexities of the cellular milieu.</p>
<p>Our analyses indicate that whilst the expression of full-length APC in SW480 cells can be expected to increase degradation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e323" xlink:type="simple"/></inline-formula>, APC overexpression in normal cells may decrease <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e324" xlink:type="simple"/></inline-formula> degradation or have no effect. We show that phosphorylation of the first 20-aa repeat in truncated APC, together with the absence of the SAMP repeats, is crucial for the effect of APC1338 on <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e325" xlink:type="simple"/></inline-formula> levels in SW480 cells (<xref ref-type="fig" rid="pcbi-1003217-g007">Figs. 7</xref> and <xref ref-type="fig" rid="pcbi-1003217-g008">8</xref>). We suggest that phosphorylated APC1338 sequesters <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e326" xlink:type="simple"/></inline-formula> from Axin, thus blocking <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e327" xlink:type="simple"/></inline-formula> phosphorylation by Axin-bound kinases, viz. <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e328" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e329" xlink:type="simple"/></inline-formula>. In contrast, phosphorylation of full-length APC, because of its SAMP repeats, which provide an indirect means for interaction between Axin and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e330" xlink:type="simple"/></inline-formula>, does not block <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e331" xlink:type="simple"/></inline-formula> association with Axin and Axin-bound kinases, except at significantly higher levels of expression (cf. panels A and B in <xref ref-type="fig" rid="pcbi-1003217-g008">Fig. 8</xref>).</p>
<p>Several experimental studies have detected competition between phosphorylated full-length APC and Axin for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e332" xlink:type="simple"/></inline-formula> binding <xref ref-type="bibr" rid="pcbi.1003217-Xing2">[24]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Ha1">[30]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Graham1">[54]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-vonKries1">[55]</xref>, although the effect of such competition on <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e333" xlink:type="simple"/></inline-formula> levels has not been previously characterized.</p>
<p>Our results suggest that APC1338, similar to full-length APC, can efficiently mediate competition with Axin for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e334" xlink:type="simple"/></inline-formula> binding, even though it lacks the third 20-aa repeat (<xref ref-type="fig" rid="pcbi-1003217-g003">Fig. 3</xref>), the high-affinity <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e335" xlink:type="simple"/></inline-formula> binding site in full-length APC. In the model, APC1338 associates with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e336" xlink:type="simple"/></inline-formula> with sufficient strength to displace Axin because of two-point attachment via its 15-aa and phosphorylated 20-aa repeat sites (i.e., because of the combined action of the interactions represented by Arrows 1 and 2 in <xref ref-type="fig" rid="pcbi-1003217-g001">Figs. 1</xref> and <xref ref-type="fig" rid="pcbi-1003217-g002">2</xref>). The single-site <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e337" xlink:type="simple"/></inline-formula>'s for the interactions mediated by these sites are <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e338" xlink:type="simple"/></inline-formula> and 80 nM, respectively <xref ref-type="bibr" rid="pcbi.1003217-Liu2">[25]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Kishida1">[43]</xref>. The affinities are comparable to the affinity of Axin for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e339" xlink:type="simple"/></inline-formula> ARM repeats 3 and 4 (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e340" xlink:type="simple"/></inline-formula> nM <xref ref-type="bibr" rid="pcbi.1003217-Kishida1">[43]</xref>). However, if two-point attachment is possible, as we have postulated in our model, then there is an avidity effect. This effect has been studied in other systems <xref ref-type="bibr" rid="pcbi.1003217-OBrien1">[56]</xref>–<xref ref-type="bibr" rid="pcbi.1003217-Kuriyan1">[58]</xref> and may confer on phosphorylated APC1338 a competitive advantage, allowing it to outcompete Axin for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e341" xlink:type="simple"/></inline-formula>.</p>
<p>A critically important feature of our model is a greater abundance of APC than Axin (<xref ref-type="table" rid="pcbi-1003217-t001">Table 1</xref>). According to our model, as discussed above, truncated APC in SW480 cells acts as a diversion sink that sequesters <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e342" xlink:type="simple"/></inline-formula> away from Axin. This diversion-sink mechanism cannot be operative if Axin is more abundant than APC. Recent measurements of APC and Axin in SW480 cells indicate that the total amounts of Axin and APC are comparable <xref ref-type="bibr" rid="pcbi.1003217-Tan1">[59]</xref>. At first, these results might seem to contradict the model presented here, which takes APC to be 10-fold more abundant than Axin. However, Axin is not homogeneously distributed in a cell. Much of the Axin in a cell is found in cytoplasmic puncta <xref ref-type="bibr" rid="pcbi.1003217-SchwarzRomond1">[35]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Faux2">[36]</xref>. Thus, only a fraction of total Axin may be available in a form capable of joining a destruction complex having the composition and structure considered here. A more complicated model than that presented here would be required to account for subcellular compartmentalization of APC, Axin and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e343" xlink:type="simple"/></inline-formula>, which clearly play an important role in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e344" xlink:type="simple"/></inline-formula> signaling <xref ref-type="bibr" rid="pcbi.1003217-Nusse1">[2]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Burgess1">[3]</xref>. Such an effort is beyond the intended scope of our study.</p>
<p>The role of colocalization of signaling proteins within the destruction complex is not completely understood. In our model, we assumed that the core of the destruction complex, formed by mutual interactions of APC, Axin, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e345" xlink:type="simple"/></inline-formula>, has a closed/cyclic structure (as depicted in the cartoon diagram at the far left of <xref ref-type="fig" rid="pcbi-1003217-g009">Fig. 9</xref>). Within this cyclic structure, there are three protein-protein interfaces, and each of the three interfaces involves interaction between two adjacent proteins, which are connected indirectly via the third protein. Therefore, the binding sites at each interface are confined together in a volume that is small relative to the total volume of the cytoplasm and the local concentrations of tethered binding partners are high. Such high local concentrations can confer on a cyclic structure more stablity than a linear structure of the same composition <xref ref-type="bibr" rid="pcbi.1003217-Jacobson1">[60]</xref>. It has been assumed that the destruction complex provides a stable platform for phosphorylation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e346" xlink:type="simple"/></inline-formula> by the Axin-recruited kinases <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e347" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e348" xlink:type="simple"/></inline-formula>. However, according to our analyses, stability of the core destruction complex (i.e., the cyclic ternary complex of APC, Axin and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e349" xlink:type="simple"/></inline-formula>) is not important for efficient degradation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e350" xlink:type="simple"/></inline-formula>. By systematically simulating ablation of each possible contact between <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e351" xlink:type="simple"/></inline-formula>, APC, and Axin, we demonstrate that stability of the complex has little if any influence on <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e352" xlink:type="simple"/></inline-formula> degradation (<xref ref-type="fig" rid="pcbi-1003217-g009">Fig. 9</xref>). (Note that the bar at the far right of <xref ref-type="fig" rid="pcbi-1003217-g009">Fig. 9</xref> is explained by the diversion-sink mechanism.) We caution that, in the model, stability of the cyclic structure is also determined by factors other than the local concentration effect. Degradation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e353" xlink:type="simple"/></inline-formula> in a core complex can terminate its cyclic structure, leaving behind a complex of APC and Axin only. In addition, phosphorylated APC can disrupt the cyclic structure by breaking the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e354" xlink:type="simple"/></inline-formula>-Axin interface through competitive binding and sequestering of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e355" xlink:type="simple"/></inline-formula> away from the complex.</p>
<p>Questions may arise as to what other roles APC plays besides destruction complex-mediated regulation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e356" xlink:type="simple"/></inline-formula> because our model indicates that elevated expression of APC in a normal cell does not have a positive effect on <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e357" xlink:type="simple"/></inline-formula> degradation (<xref ref-type="fig" rid="pcbi-1003217-g005">Fig. 5A</xref>), i.e., an increase in APC abundance is not predicted to cause a decrease in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e358" xlink:type="simple"/></inline-formula> level. A variety of other potential functions of APC have been suggested. Phosphorylated APC has been implicated in subcellular localization and nuclear shuttling of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e359" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003217-Seo1">[32]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Bienz1">[61]</xref>–<xref ref-type="bibr" rid="pcbi.1003217-RosinArbesfeld1">[63]</xref>, and high-affinity binding of phosphorylated APC with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e360" xlink:type="simple"/></inline-formula> has been suggested to disrupt <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e361" xlink:type="simple"/></inline-formula> interaction with other binding partners, such as E-cadherin and the Tcf and Lef family transcription factors <xref ref-type="bibr" rid="pcbi.1003217-Xing2">[24]</xref>. It has been shown that APC competes with E-cadherin for binding to the ARM repeat region of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e362" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003217-Hlsken1">[64]</xref>. Indeed, the main effect of stable expression of full-length APC in SW480 cells is not a reduction of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e363" xlink:type="simple"/></inline-formula> level (although there is an approximate 2-fold reduction in the total amount of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e364" xlink:type="simple"/></inline-formula>), but rather a redistribution of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e365" xlink:type="simple"/></inline-formula> from the nuclear and cytosolic compartments to the plasma membrane <xref ref-type="bibr" rid="pcbi.1003217-Faux1">[34]</xref>. Transient expression of APC (at higher levels) causes a more dramatic reduction in the level of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e366" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003217-Munemitsu1">[31]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Faux1">[34]</xref>. In future work, it would be interesting to investigate how E-cadherin may regulate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e367" xlink:type="simple"/></inline-formula> and <italic>vice versa</italic> <xref ref-type="bibr" rid="pcbi.1003217-Burgess1">[3]</xref>.</p>
<p>Our study identifies <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e368" xlink:type="simple"/></inline-formula> as a potential target for therapeutic intervention in colorectal cancer. Inhibiting <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e369" xlink:type="simple"/></inline-formula> is expected to reverse the effect of truncation of APC in SW480 cells. According to the model, phosphorylation of APC1338 at the first 20-aa repeat plays a key role in upregulating <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e370" xlink:type="simple"/></inline-formula> in cancer cells (<xref ref-type="fig" rid="pcbi-1003217-g007">Fig. 7</xref>). Therefore, inhibition of phosphorylation of APC at this site might be an effective way to normalize <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e371" xlink:type="simple"/></inline-formula> levels in cancer cells. Phosphorylation of APC requires the combined action of two kinases, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e372" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e373" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003217-Ha1">[30]</xref>. Therefore, blocking of either kinase is predicted to reduce APC phosphorylation, as shown by Ha et al. <xref ref-type="bibr" rid="pcbi.1003217-Ha1">[30]</xref>. Because <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e374" xlink:type="simple"/></inline-formula> is a common kinase for both <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e375" xlink:type="simple"/></inline-formula> and APC (<xref ref-type="fig" rid="pcbi-1003217-g001">Fig. 1</xref>) and its inhibition would stabilize <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e376" xlink:type="simple"/></inline-formula>, only <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e377" xlink:type="simple"/></inline-formula> is a potential target. We note that targeting of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e378" xlink:type="simple"/></inline-formula> should be feasible in preclinical studies, as pharamacological kinase inhibitors specific to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e379" xlink:type="simple"/></inline-formula> are available <xref ref-type="bibr" rid="pcbi.1003217-Behrend1">[65]</xref>–<xref ref-type="bibr" rid="pcbi.1003217-Walton1">[67]</xref>.</p>
<p>In this study, we used a detailed mechanistic modeling approach based on the principles of chemical kinetics to investigate regulation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e380" xlink:type="simple"/></inline-formula> phosphorylation and degradation by full-length and truncated APC. In a previous study, Lee et al. <xref ref-type="bibr" rid="pcbi.1003217-Lee1">[53]</xref> developed a related model to investigate regulation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e381" xlink:type="simple"/></inline-formula> by Wnt stimulation. However, this model does not consider truncated APC. Another notable difference is that the model of Lee et al. <xref ref-type="bibr" rid="pcbi.1003217-Lee1">[53]</xref> is an ordinary differential equation (ODE)-based model, wherein molecules and complexes of signaling proteins are treated as reactive chemical species, which must be enumerated along with all possible reactions to obtain an executable model. In contrast, because of the goals of our study, we developed our model using the rule-based modeling approach <xref ref-type="bibr" rid="pcbi.1003217-Hlavacek1">[37]</xref>–<xref ref-type="bibr" rid="pcbi.1003217-Chylek1">[40]</xref>. With this approach, local rules are used to represent protein-protein interactions, which are assumed to be modular. Assumptions of modularity can greatly reduce the complexity of a model for protein-protein interactions, and as a result, enable explicit consideration of multiple functional components within proteins (e.g., the multiple sites of phosphorylation in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e382" xlink:type="simple"/></inline-formula>). In our model, the components of the proteins considered are the basic reactive elements, i.e., we consider biochemical reactions, such as reversible binding and phosphorylation, to occur at the level of protein sites. This approach was critical for the goals of our study, which included a characterization of the effects of loss of sites in APC. Such effects, and biomolecular site dynamics in general, are difficult to capture in an ODE model <xref ref-type="bibr" rid="pcbi.1003217-Chylek1">[40]</xref>. The study presented here provides an example of how rule-based modeling, a fairly new approach in biology, can be used to study biomolecular site dynamics.</p>
<p>We focused on a part of the Wnt/<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e383" xlink:type="simple"/></inline-formula> signaling pathway that controls <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e384" xlink:type="simple"/></inline-formula> degradation and expression level. Our primary goal was to understand the differential regulation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e385" xlink:type="simple"/></inline-formula> in normal and cancer cells at steady state and in the absence of Wnt signals, unlike in other modeling studies that have focused on the dynamics of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e386" xlink:type="simple"/></inline-formula> regulation in response to a Wnt ligand <xref ref-type="bibr" rid="pcbi.1003217-Hernndez1">[20]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Lee1">[53]</xref>. In future work, it would be interesting to extend our model by connecting it to other components of the Wnt/<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e387" xlink:type="simple"/></inline-formula> signaling pathway and to further investigate the dynamics of regulation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e388" xlink:type="simple"/></inline-formula>.</p>
</sec><sec id="s4" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="s4a">
<title>Parameter values</title>
<p>Model parameter values are listed in <xref ref-type="table" rid="pcbi-1003217-t001">Table 1</xref>. Most of the parameter values are based on previously reported estimates. However, some parameter values were set to allow the model to capture a set of observed system behaviors.</p>
<p>In the model, the concentration of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e389" xlink:type="simple"/></inline-formula> depends in part on its rates of synthesis and degradation. As discussed below, we set parameters for these and other processes considered in the model such that the nominal, steady-state concentration of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e390" xlink:type="simple"/></inline-formula> is 35 nM <xref ref-type="bibr" rid="pcbi.1003217-Lee1">[53]</xref>, which corresponds to 11,000 copies/cell assuming a cytoplasmic volume of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e391" xlink:type="simple"/></inline-formula> L <xref ref-type="bibr" rid="pcbi.1003217-Tan1">[59]</xref>. This concentration is consistent with the concentration of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e392" xlink:type="simple"/></inline-formula> measured in <italic>Xenopus</italic> egg extract <xref ref-type="bibr" rid="pcbi.1003217-Lee1">[53]</xref>. It is also consistent with the cytosolic (but not total) concentration of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e393" xlink:type="simple"/></inline-formula> measured in HEK293T and MDCK cells, kidney epithelial cell lines, and in Caco-2 cells <xref ref-type="bibr" rid="pcbi.1003217-Tan1">[59]</xref>, an intestinal cell line. We take both APC and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e394" xlink:type="simple"/></inline-formula> concentration to be 100 nM (31,540 copies/cell). Concentrations of APC and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e395" xlink:type="simple"/></inline-formula> have been measured to be 100 nM and 50 nM, respectively, in <italic>Xenopus</italic> egg extract <xref ref-type="bibr" rid="pcbi.1003217-Lee1">[53]</xref>, and measured concentrations of these proteins in mammalian cells fall in the ranges of 4–34 nM and 10–120 nM, respectively <xref ref-type="bibr" rid="pcbi.1003217-Tan1">[59]</xref>. We take <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e396" xlink:type="simple"/></inline-formula> concentration to be the same as <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e397" xlink:type="simple"/></inline-formula>, 100 nM. We assume Axin to be present at 10 nM (3,154 copy/cell), which is consistent with recent measurements of Axin abundance in mammalian cells; the Axin concentration measured in mammalian cells ranges from 20 to 150 nM <xref ref-type="bibr" rid="pcbi.1003217-Tan1">[59]</xref>. Lee et al. <xref ref-type="bibr" rid="pcbi.1003217-Lee1">[53]</xref> reported that Axin is present in <italic>Xenopus</italic> egg extract at a very low concentration, in the range of 10 to 20 pM <xref ref-type="bibr" rid="pcbi.1003217-Lee1">[53]</xref>. We rejected this value, while accepting and using the qualitative observation of Lee et al. <xref ref-type="bibr" rid="pcbi.1003217-Lee1">[53]</xref> that Axin is less abundant than APC, because a concentration of 20 pM corresponds to only six copies of Axin per cell for a human epithelial cell, which as stated above is taken to have a cytoplasmic volume of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e398" xlink:type="simple"/></inline-formula> L <xref ref-type="bibr" rid="pcbi.1003217-Tan1">[59]</xref>.</p>
<p>For association of any two proteins that are not already in a complex together we assume the same forward rate constant (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e399" xlink:type="simple"/></inline-formula>) for all interactions: <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e400" xlink:type="simple"/></inline-formula> (<xref ref-type="table" rid="pcbi-1003217-t001">Table 1</xref>). Each reverse rate constant (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e401" xlink:type="simple"/></inline-formula>) is determined from the relation <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e402" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e403" xlink:type="simple"/></inline-formula> is the equilibrium dissociation constant for the reaction of interest. Equilibrium dissociation constants are set at values reported earlier in the literature, as indicated below.</p>
<p>In the model, the region in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e404" xlink:type="simple"/></inline-formula> containing ARM repeats 5–9 interacts with the 15-aa repeat region in APC (Arrow 1) with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e405" xlink:type="simple"/></inline-formula> nM (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e406" xlink:type="simple"/></inline-formula>) <xref ref-type="bibr" rid="pcbi.1003217-Kishida1">[43]</xref>. The region in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e407" xlink:type="simple"/></inline-formula> containing ARM repeats 3 and 4 interacts with the phosphorylated 20-aa region in APC (Arrow 2) with an affinity that depends on whether APC is full length or truncated (APC1338). Phosphorylated full-length APC binds the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e408" xlink:type="simple"/></inline-formula> ARM repeats 3 and 4 with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e409" xlink:type="simple"/></inline-formula> nM (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e410" xlink:type="simple"/></inline-formula>), whereas phosphorylated APC1338 binds with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e411" xlink:type="simple"/></inline-formula> nM (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e412" xlink:type="simple"/></inline-formula>) <xref ref-type="bibr" rid="pcbi.1003217-Liu2">[25]</xref>. We assume that APC binds <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e413" xlink:type="simple"/></inline-formula> via only a single 20-aa repeat, which is consistent with binding of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e414" xlink:type="simple"/></inline-formula> at one 20-aa repeat sterically hindering binding of additional copies of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e415" xlink:type="simple"/></inline-formula> at other 20-aa repeats. When phosphorylated, the third 20-aa repeat mediates binding with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e416" xlink:type="simple"/></inline-formula> nM, whereas the other six 20-aa repeats appear to bind with much lower affinites <xref ref-type="bibr" rid="pcbi.1003217-Liu2">[25]</xref>. <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e417" xlink:type="simple"/></inline-formula> binds the central region of Axin via ARM repeats 3 and 4 (Arrow 3) with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e418" xlink:type="simple"/></inline-formula> nM (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e419" xlink:type="simple"/></inline-formula>) <xref ref-type="bibr" rid="pcbi.1003217-Kishida1">[43]</xref>. <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e420" xlink:type="simple"/></inline-formula> binds the Axin GID domain (Arrow 5) with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e421" xlink:type="simple"/></inline-formula> nM (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e422" xlink:type="simple"/></inline-formula>) <xref ref-type="bibr" rid="pcbi.1003217-Ikeda2">[68]</xref>. We assume that APC and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e423" xlink:type="simple"/></inline-formula> bind Axin (Arrow 4 and 6, respectively) with the same <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e424" xlink:type="simple"/></inline-formula>: <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e425" xlink:type="simple"/></inline-formula> nM (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e426" xlink:type="simple"/></inline-formula>) and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e427" xlink:type="simple"/></inline-formula> nM (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e428" xlink:type="simple"/></inline-formula>).</p>
<p>In the model, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e429" xlink:type="simple"/></inline-formula> level is determined not only by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e430" xlink:type="simple"/></inline-formula> synthesis and degradation rate constants, but also by other parameters that affect the phosphorylation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e431" xlink:type="simple"/></inline-formula> and APC. These parameters include phosphorylation and dephosphorylation rate constants and the enhancement factor <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e432" xlink:type="simple"/></inline-formula>. All of these parameters directly or indirectly determine the total level of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e433" xlink:type="simple"/></inline-formula>. We selected values for these parameters, which are given in <xref ref-type="table" rid="pcbi-1003217-t001">Table 1</xref>, such that the model captures a set of experimentally-observed system behaviors.</p>
<p>With the parameter values listed in <xref ref-type="table" rid="pcbi-1003217-t001">Table 1</xref>, the model reproduces a steady-state concentration of (cytosolic) <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e434" xlink:type="simple"/></inline-formula> of 35 nM, which as discussed above is consistent with some measurements <xref ref-type="bibr" rid="pcbi.1003217-Lee1">[53]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Tan1">[59]</xref>. Furthermore, the model predicts the effective half-life of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e435" xlink:type="simple"/></inline-formula> to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e436" xlink:type="simple"/></inline-formula> min, and the half-life of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e437" xlink:type="simple"/></inline-formula> mutated at S33/S37 to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e438" xlink:type="simple"/></inline-formula> h, which is consistent with the observations of Rubinfeld et al. <xref ref-type="bibr" rid="pcbi.1003217-Rubinfeld1">[14]</xref> (<xref ref-type="supplementary-material" rid="pcbi.1003217.s001">Fig. S1</xref>). The model also reproduces the experimentally-determined kinetics of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e439" xlink:type="simple"/></inline-formula> dephosphorylation at distinct phosphorylation sites in response to treatment with LiCl, an inhibitor of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e440" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003217-Liu1">[12]</xref> (<xref ref-type="supplementary-material" rid="pcbi.1003217.s002">Fig. S2</xref>). The consistency of the model with observed system behaviors is further discussed in the <xref ref-type="sec" rid="s2">Results</xref> section.</p>
<p>We note that the model is not entirely consistent with recent measurements of APC, Axin, (cytosolic) <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e441" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e442" xlink:type="simple"/></inline-formula> concentrations in SW480 cells <xref ref-type="bibr" rid="pcbi.1003217-Tan1">[59]</xref>. The model cannot simultaneously reproduce these concentrations and observed system behaviors. This could be because the measured concentrations do not reflect the subcellular concentrations relevant for destruction complex function. Alternatively, our mechanistic knowledge of destruction complex function could be incomplete. We formulated our model to probe the limits of understanding of destruction complex function. In setting parameter values, we put an emphasis on selecting values that allow the model to reproduce observed system behaviors, rather than measured system parameters (viz., protein concentrations). This approach is guided by findings from computational analyses of model sloppiness, which indicate that fitting tends to improve the accuracy of model predictions more than parameter measurement <xref ref-type="bibr" rid="pcbi.1003217-Gutenkunst1">[69]</xref>.</p>
</sec><sec id="s4b">
<title>Model specification</title>
<p>We will refer to the model illustrated in <xref ref-type="fig" rid="pcbi-1003217-g001">Figs. 1</xref> and <xref ref-type="fig" rid="pcbi-1003217-g002">2</xref> as the base model. The base model corresponds to the case of a normal cell with full-length APC. Variants of the base model correspond to SW480 cells with APC1338, SW480 cells transfected with different forms of APC, and other cases considered in this study (see below for further details). The base model and each of its variants was formulated using BNGL, a model-specification language <xref ref-type="bibr" rid="pcbi.1003217-Faeder2">[39]</xref>. Executable model-specification files are provided in the Supporting Information for the base model (<xref ref-type="supplementary-material" rid="pcbi.1003217.s005">Text S2</xref>) and its variants (<xref ref-type="supplementary-material" rid="pcbi.1003217.s006">Text S3</xref>, <xref ref-type="supplementary-material" rid="pcbi.1003217.s007">S4</xref>, <xref ref-type="supplementary-material" rid="pcbi.1003217.s008">S5</xref>, <xref ref-type="supplementary-material" rid="pcbi.1003217.s009">S6</xref>, <xref ref-type="supplementary-material" rid="pcbi.1003217.s010">S7</xref>, <xref ref-type="supplementary-material" rid="pcbi.1003217.s011">S8</xref>, <xref ref-type="supplementary-material" rid="pcbi.1003217.s012">S9</xref>, <xref ref-type="supplementary-material" rid="pcbi.1003217.s013">S10</xref>). BNGL is compatible with BioNetGen <xref ref-type="bibr" rid="pcbi.1003217-Faeder2">[39]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Blinov1">[70]</xref>, a software tool for rule-based modeling, and a number of other tools, such as RuleBender <xref ref-type="bibr" rid="pcbi.1003217-Xu1">[71]</xref>, an interface for BioNetGen. In addition to parameter values and initial data, each model-specification included molecule type definitions and rules. Molecule type definitions delimit the functional components of proteins and their possible phosphorylation states. The rules characterize protein-protein interactions and other processes (viz., synthesis and degradation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e443" xlink:type="simple"/></inline-formula>). The rules that characterize protein-protein interactions can be subdivided into 10 sets, with one set for each arrow in <xref ref-type="fig" rid="pcbi-1003217-g001">Fig. 1</xref> or 2. An arrow corresponds to multiple rules if the interaction represented by the rule can take place in multiple contexts and the context influences the rate of reaction. For example, Arrow 3 in <xref ref-type="fig" rid="pcbi-1003217-g001">Fig. 1</xref> or 2 represents an interaction that can take place between either unconnected proteins or tethered proteins. Thus, there is a rule for each of these two cases.</p>
</sec><sec id="s4c">
<title>Simulation</title>
<p>The base model (<xref ref-type="fig" rid="pcbi-1003217-g001">Figs. 1</xref> and <xref ref-type="fig" rid="pcbi-1003217-g002">2</xref>) and each variant model was simulated by submitting the corresponding model-specficiation file to BioNetGen <xref ref-type="bibr" rid="pcbi.1003217-Faeder2">[39]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Blinov1">[70]</xref> for processing. Model-specification files are provided in the Supporting Information (<xref ref-type="supplementary-material" rid="pcbi.1003217.s005">Text S2</xref>, <xref ref-type="supplementary-material" rid="pcbi.1003217.s006">S3</xref>, <xref ref-type="supplementary-material" rid="pcbi.1003217.s007">S4</xref>, <xref ref-type="supplementary-material" rid="pcbi.1003217.s008">S5</xref>, <xref ref-type="supplementary-material" rid="pcbi.1003217.s009">S6</xref>, <xref ref-type="supplementary-material" rid="pcbi.1003217.s010">S7</xref>, <xref ref-type="supplementary-material" rid="pcbi.1003217.s011">S8</xref>, <xref ref-type="supplementary-material" rid="pcbi.1003217.s012">S9</xref>, <xref ref-type="supplementary-material" rid="pcbi.1003217.s013">S10</xref>); the format of these files is plain text. Simulation protocols are included in each model-specification file. The captions of figures indicate which model-specification files were used in calculations. In all cases, the method used for simulation was an indirect method, meaning that the rules of the model being simulated were not used directly in the simulation procedure. Rather, the rules were expanded (i.e., used to exhaustively enumerate the distinct chemical species and individual chemical reactions implied by the rules) by invoking the generate_network function of BioNetGen to obtain a reaction network. The corresponding system of ODEs describing the mass-action kinetics of this network were then numerically integrated by invoking the simulate_ode function of BioNetGen. BioNetGen uses CVODE <xref ref-type="bibr" rid="pcbi.1003217-Cohen1">[72]</xref>, <xref ref-type="bibr" rid="pcbi.1003217-Hindmarsh1">[73]</xref> for numerical integration of ODEs. For the base model, the reaction network obtained by expansion of its rules comprises 410 distinct chemical species. The size of this network does not reflect the intrinsic complexity of the base model. Rather, the intrinsic complexity of this model is reflected by the number of its rules. The base model includes 29 rules. We used scripts to systematically vary default parameter values specified in BioNetGen input files to produce many of the figures shown in the <xref ref-type="sec" rid="s2">Results</xref> section. Parameter scans are enabled by a function available within RuleBender <xref ref-type="bibr" rid="pcbi.1003217-Xu1">[71]</xref>.</p>
</sec></sec><sec id="s5">
<title>Supporting Information</title>
<supplementary-material id="pcbi.1003217.s001" mimetype="application/postscript" xlink:href="info:doi/10.1371/journal.pcbi.1003217.s001" position="float" xlink:type="simple"><label>Figure S1</label><caption>
<p><bold>The model reproduces the half-lives of </bold><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e444" xlink:type="simple"/></inline-formula><bold> and </bold><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e445" xlink:type="simple"/></inline-formula><bold> mutated at S33/S37.</bold> The model predicts the half-life of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e446" xlink:type="simple"/></inline-formula> in a normal cell to be 30 min (solid line) and the half-life of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e447" xlink:type="simple"/></inline-formula> mutated at the S33/S37 phosphorylation site to be 4.5 h (dashed line). These predicted values are consistent with the measured values reported by Rubinfeld et al. <xref ref-type="bibr" rid="pcbi.1003217-Rubinfeld1">[14]</xref>. The figure illustrates model-predicted decay of cellular <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e448" xlink:type="simple"/></inline-formula> or <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e449" xlink:type="simple"/></inline-formula> mutated at S33/S37 in a simulated pulse-chase experiment <xref ref-type="bibr" rid="pcbi.1003217-Rubinfeld1">[14]</xref>. The model was used to simulate the pulse-chase experiments of Rubenfield et al. <xref ref-type="bibr" rid="pcbi.1003217-Rubinfeld1">[14]</xref>, which were carried out to determine the half-lives of the proteins.</p>
<p>(EPS)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003217.s002" mimetype="application/postscript" xlink:href="info:doi/10.1371/journal.pcbi.1003217.s002" position="float" xlink:type="simple"><label>Figure S2</label><caption>
<p><bold>The model reproduces the effects of LiCl treatment on phosphorylation of cellular </bold><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e450" xlink:type="simple"/></inline-formula><bold>.</bold> The figure shows predicted and measured phosphorylation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e451" xlink:type="simple"/></inline-formula> at S45 and S33/S37 in response to LiCl treatment of cells. The solid lines represent model predictions, and the points represent experimental data of Liu et al. <xref ref-type="bibr" rid="pcbi.1003217-Liu1">[12]</xref>. The solid line/filled circles correspond to S45, and the dashed line/open circles correspond to S33/S37. In the model, LiCl addition is simulated by assuming a 20-fold decrease in kinase activity of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e452" xlink:type="simple"/></inline-formula> (i.e., 20-fold reduced rate of phosphorylation of the APC 20-aa repeats and S33/S37 in <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e453" xlink:type="simple"/></inline-formula>). The kinase activities of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e454" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e455" xlink:type="simple"/></inline-formula> are assumed to be unaffected by LiCl treatment. Time <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e456" xlink:type="simple"/></inline-formula> represents the time of LiCl addition. The <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e457" xlink:type="simple"/></inline-formula> values represent phosphorylation of S45 or S33/S37 relative to the steady-state levels of phosphorylation of these sites in the absence of LiCl.</p>
<p>(EPS)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003217.s003" mimetype="application/pdf" xlink:href="info:doi/10.1371/journal.pcbi.1003217.s003" position="float" xlink:type="simple"><label>Table S1</label><caption>
<p><bold>Local parameter sensitivity analysis.</bold> The steady-state level of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e458" xlink:type="simple"/></inline-formula> is insensitive to variations of model parameter values, as assessed by local sensitivity coefficients.</p>
<p>(PDF)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003217.s004" mimetype="text/plain" xlink:href="info:doi/10.1371/journal.pcbi.1003217.s004" position="float" xlink:type="simple"><label>Text S1</label><caption>
<p><bold>Model annotation wiki.</bold> This TiddlyWiki (tiddlywiki.com), which takes the form of a single HTML file, provides extensive annotation of the molecule type definitions and rules that comprise the base model, as well as discussion of various modeling assumptions. The wiki can be viewed and navigated using a Web browser. It contains links to relevant information available in public online resources, including UniProt <xref ref-type="bibr" rid="pcbi.1003217-Jain1">[75]</xref>, OMIM <xref ref-type="bibr" rid="pcbi.1003217-Amberger1">[76]</xref>, and Pfam <xref ref-type="bibr" rid="pcbi.1003217-Finn1">[77]</xref>.</p>
<p>(TXT)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003217.s005" mimetype="text/plain" xlink:href="info:doi/10.1371/journal.pcbi.1003217.s005" position="float" xlink:type="simple"><label>Text S2</label><caption>
<p><bold>BioNetGen input file for model illustrated in </bold><xref ref-type="fig" rid="pcbi-1003217-g001"><bold>Figs. 1</bold></xref><bold> and </bold><xref ref-type="fig" rid="pcbi-1003217-g002"><bold>2</bold></xref><bold>.</bold> This file, which can be processed by BioNetGen (after changing the file name extension to .bngl), provides a complete executable specification of the base model <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e459" xlink:type="simple"/></inline-formula>, i.e., the model for a normal cell with full-length APC. In this model, the low-affinity interaction of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e460" xlink:type="simple"/></inline-formula> with the first (phosphorylated) 20-aa repeat in APC (Arrow 2 in <xref ref-type="fig" rid="pcbi-1003217-g001">Figs. 1</xref> and <xref ref-type="fig" rid="pcbi-1003217-g002">2</xref>) is omitted for simplicity. This simplification does not prevent interaction of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e461" xlink:type="simple"/></inline-formula> with phosphorylated APC, because a rule is included for the (dominant) high-affinity interaction of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e462" xlink:type="simple"/></inline-formula> with the third (phosphorylated) 20-aa repeat (Arrow 2 in <xref ref-type="fig" rid="pcbi-1003217-g001">Figs. 1</xref> and <xref ref-type="fig" rid="pcbi-1003217-g002">2</xref>). Note that the base model and all of its variants include rules not only for the interactions illustrated in <xref ref-type="fig" rid="pcbi-1003217-g001">Figs. 1</xref> and <xref ref-type="fig" rid="pcbi-1003217-g002">2</xref> but also for synthesis and degradation of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e463" xlink:type="simple"/></inline-formula> as well as rules for dephosphorylation of APC and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e464" xlink:type="simple"/></inline-formula>. We note that this file can be viewed as specifying a model for a normal cell transfected with APC-A (full-length APC, APC2 or APC 4) (<xref ref-type="fig" rid="pcbi-1003217-g003">Fig. 3</xref>). All forms of APC-A are taken to be functionally equivalent to full-length APC, because each form contains the same functional components that are considered in the base model for full-length APC (15-aa repeats, 20-aa repeats, and SAMP repeats). In simulated transfections of APC-A, the amount of added APC-A (taken to be equivalent to an increase in full-length APC) was varied systematically. See the Simulation subsection in the <xref ref-type="sec" rid="s4">Materials and Methods</xref> section for more information.</p>
<p>(TXT)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003217.s006" mimetype="text/plain" xlink:href="info:doi/10.1371/journal.pcbi.1003217.s006" position="float" xlink:type="simple"><label>Text S3</label><caption>
<p><bold>BioNetGen input file for model variant 1.</bold> This file specifies the model for an SW480 cell with truncated APC (APC1338). This model (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e465" xlink:type="simple"/></inline-formula>) differs from <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e466" xlink:type="simple"/></inline-formula> in that full-length APC is replaced by APC1338, meaning that the rule for interaction of Axin with the SAMP repeats in APC is removed (Arrow 4 in <xref ref-type="fig" rid="pcbi-1003217-g001">Figs. 1</xref> and <xref ref-type="fig" rid="pcbi-1003217-g002">2</xref>) and the rule for high-affinity interaction of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e467" xlink:type="simple"/></inline-formula> with the third (phosphorylated) 20-aa repeat is replaced by a rule for the low-affinity interaction of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e468" xlink:type="simple"/></inline-formula> with the first (phosphorylated) 20-aa repeat (Arrow 2 in <xref ref-type="fig" rid="pcbi-1003217-g001">Figs. 1</xref> and <xref ref-type="fig" rid="pcbi-1003217-g002">2</xref>). Other interactions involving APC remain the same. These changes are intended to capture the effects of C-terminal truncation of APC, which commonly and in the case of APC1338 means a loss of the SAMP repeats and all but the first 20-aa repeat. We note that this file can also be viewed as specifying a model for an SW480 cell transfected with APC-B or APC-F. Recall that the APC-F class of proteins (APC 3, APC arm, and APC 20) do not contain any of the functional components of full-length APC considered in the model (<xref ref-type="fig" rid="pcbi-1003217-g003">Fig. 3</xref>). Thus, in the model, APC-F does not participate in any interactions (i.e., there are no rules that involve APC-F). Recall that APC-B includes APC 21 and APC 22 (<xref ref-type="fig" rid="pcbi-1003217-g003">Fig. 3</xref>), both of which are taken to be functionally equivalent to APC1338 because these forms of APC, like APC1338, each includes 15-aa repeats and the first 20-aa repeat. Thus, rules for APC1338 interactions are the same as rules for APC-B interactions. In simulated transfections of APC-B, the amount of added APC-B (taken to be equivalent to an increase in endogenous APC1338) was systematically varied. Finally, we note that this file was used for simulating the effect of varying the rate at which the 20-aa repeat region in APC is phosphorylated. In these simulations, the rate constant for APC phosphorylation (denoted as <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e469" xlink:type="simple"/></inline-formula> in <xref ref-type="table" rid="pcbi-1003217-t001">Table 1</xref> and as kp in model-specification files) was systematically varied.</p>
<p>(TXT)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003217.s007" mimetype="text/plain" xlink:href="info:doi/10.1371/journal.pcbi.1003217.s007" position="float" xlink:type="simple"><label>Text S4</label><caption>
<p><bold>BioNetGen input file for model variant 2.</bold> This file specifies a model for an SW480 cell (i.e., a cell expressing APC1338 endogenously) transfected with APC-A (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e470" xlink:type="simple"/></inline-formula>). The amount of added APC-A was systematically varied in simulations. Recall that APC-A includes full-length APC, APC 2 and APC 4 (<xref ref-type="fig" rid="pcbi-1003217-g003">Fig. 3</xref>), which are taken to be functionally equivalent because these forms of APC contain 15-aa repeats, all 20-aa repeats, and SAMP repeats. In this model, separate rules are specified for APC1338 and APC-A interactions. The rules account for all of the APC interactions considered in models <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e471" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e472" xlink:type="simple"/></inline-formula>.</p>
<p>(TXT)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003217.s008" mimetype="text/plain" xlink:href="info:doi/10.1371/journal.pcbi.1003217.s008" position="float" xlink:type="simple"><label>Text S5</label><caption>
<p><bold>BioNetGen input file for model variant 3.</bold> This file specifies a model for an SW480 cell transfected with APC-C (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e473" xlink:type="simple"/></inline-formula>). The amount of added APC-C was systematically varied in simulations. Recall that APC-C includes APC 21 and APC 22 (<xref ref-type="fig" rid="pcbi-1003217-g003">Fig. 3</xref>), which are taken to be functionally equivalent because both of these forms of APC contain 15-aa repeats while missing all 20-aa repeats and the SAMP repeats. In this model, separate rules are specified for APC1388 and APC-C interactions. The only interaction in which APC-C can participate is the constitutive interaction between APC and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e474" xlink:type="simple"/></inline-formula> (Arrow 1 in <xref ref-type="fig" rid="pcbi-1003217-g001">Figs. 1</xref> and <xref ref-type="fig" rid="pcbi-1003217-g002">2</xref>).</p>
<p>(TXT)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003217.s009" mimetype="text/plain" xlink:href="info:doi/10.1371/journal.pcbi.1003217.s009" position="float" xlink:type="simple"><label>Text S6</label><caption>
<p><bold>BioNetGen input file for model variant 4.</bold> This file specifies a model for an SW480 cell transfected with APC-D (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e475" xlink:type="simple"/></inline-formula>). The amount of added APC-D was systematically varied in simulations. Recall that APC-D includes only APC 23 (<xref ref-type="fig" rid="pcbi-1003217-g003">Fig. 3</xref>), which contains only the first 20-aa repeat. Although APC-D contains a 20-aa repeat, APC-D cannot be phosphorylated because it lacks other components needed for association with Axin. Thus, this model is essentially the same as model <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e476" xlink:type="simple"/></inline-formula>.</p>
<p>(TXT)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003217.s010" mimetype="text/plain" xlink:href="info:doi/10.1371/journal.pcbi.1003217.s010" position="float" xlink:type="simple"><label>Text S7</label><caption>
<p><bold>BioNetGen input file for model variant 5.</bold> This file specifies a model for an SW480 cell transfected with APC-E (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e477" xlink:type="simple"/></inline-formula>). The amount of added APC-E (or APC 25, <xref ref-type="fig" rid="pcbi-1003217-g003">Fig. 3</xref>) was systematically varied in simulations. In this model, separate rules are specified for APC1388 and APC-E interactions. APC-E participates in the same interactions as APC1338 except for the constitutive interaction between APC and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e478" xlink:type="simple"/></inline-formula> (Arrow 1 in <xref ref-type="fig" rid="pcbi-1003217-g001">Figs. 1</xref> and <xref ref-type="fig" rid="pcbi-1003217-g002">2</xref>), which is mediated by the 15-aa repeats that are missing in APC-E.</p>
<p>(TXT)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003217.s011" mimetype="text/plain" xlink:href="info:doi/10.1371/journal.pcbi.1003217.s011" position="float" xlink:type="simple"><label>Text S8</label><caption>
<p><bold>BioNetGen input file for model variant 6.</bold> This model (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e479" xlink:type="simple"/></inline-formula>) is the same as <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e480" xlink:type="simple"/></inline-formula> except that the association rate constant for APC binding to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e481" xlink:type="simple"/></inline-formula> <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e482" xlink:type="simple"/></inline-formula> (denoted as kf1_bap in model-specification files) has been set to 0. Note that <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e483" xlink:type="simple"/></inline-formula> characterizes the interaction represented by Arrow 1 in <xref ref-type="fig" rid="pcbi-1003217-g001">Figs. 1</xref> and <xref ref-type="fig" rid="pcbi-1003217-g002">2</xref>.</p>
<p>(TXT)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003217.s012" mimetype="text/plain" xlink:href="info:doi/10.1371/journal.pcbi.1003217.s012" position="float" xlink:type="simple"><label>Text S9</label><caption>
<p><bold>BioNetGen input file for model variant 7.</bold> This model (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e484" xlink:type="simple"/></inline-formula>) is the same as <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e485" xlink:type="simple"/></inline-formula> except that the association rate constant for Axin binding to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e486" xlink:type="simple"/></inline-formula> (denoted as <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e487" xlink:type="simple"/></inline-formula> in <xref ref-type="table" rid="pcbi-1003217-t001">Table 1</xref> and as kf_ba in model-specification files) has been set to 0. Recall that Arrow 3 in <xref ref-type="fig" rid="pcbi-1003217-g001">Figs. 1</xref> and <xref ref-type="fig" rid="pcbi-1003217-g002">2</xref> represents the interaction between Axin and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e488" xlink:type="simple"/></inline-formula>.</p>
<p>(TXT)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003217.s013" mimetype="text/plain" xlink:href="info:doi/10.1371/journal.pcbi.1003217.s013" position="float" xlink:type="simple"><label>Text S10</label><caption>
<p><bold>BioNetGen input file for model variant 8.</bold> This model (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e489" xlink:type="simple"/></inline-formula>) is the same as <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e490" xlink:type="simple"/></inline-formula> except that the association rate constant for APC binding to Axin (denoted as <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003217.e491" xlink:type="simple"/></inline-formula> in <xref ref-type="table" rid="pcbi-1003217-t001">Table 1</xref> and as kf_apa in model-specification files) has been set to 0. Recall that Arrow 4 in <xref ref-type="fig" rid="pcbi-1003217-g001">Figs. 1</xref> and <xref ref-type="fig" rid="pcbi-1003217-g002">2</xref> represents the interaction between APC and Axin.</p>
<p>(TXT)</p>
</caption></supplementary-material></sec></body>
<back>
<ack>
<p>We thank Antony W. Burgess for helpful discussions.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pcbi.1003217-Clevers1"><label>1</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Clevers</surname><given-names>H</given-names></name> (<year>2006</year>) <article-title>Wnt/<italic>β</italic>–catenin signaling in development and disease</article-title>. <source>Cell</source> <volume>127</volume>: <fpage>469</fpage>–<lpage>80</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Nusse1"><label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nusse</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Varmus</surname><given-names>H</given-names></name> (<year>2012</year>) <article-title>Three decades of Wnt: a personal perspective on how a scientific field developed</article-title>. <source>EMBO J</source> <volume>31</volume>: <fpage>2670</fpage>–<lpage>84</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Burgess1"><label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Burgess</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Faux</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Layton</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ramsay</surname><given-names>R</given-names></name> (<year>2011</year>) <article-title>Wnt signaling and colon tumorigenesis — a view from the periphery</article-title>. <source>Exp Cell Res</source> <volume>317</volume>: <fpage>2748</fpage>–<lpage>58</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Behrens1"><label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Behrens</surname><given-names>J</given-names></name>, <name name-style="western"><surname>von Kries</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Kühl</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bruhn</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wedlich</surname><given-names>D</given-names></name>, <etal>et al</etal>. (<year>1996</year>) <article-title>Functional interaction of <italic>β</italic>–catenin with the transcription factor LEF-1</article-title>. <source>Nature</source> <volume>382</volume>: <fpage>638</fpage>–<lpage>42</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Molenaar1"><label>5</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Molenaar</surname><given-names>M</given-names></name>, <name name-style="western"><surname>van de Wetering</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Oosterwegel</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Peterson-Maduro</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Godsave</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>1996</year>) <article-title>XTcf-3 transcription factor mediates <italic>β</italic>–catenin-induced axis formation in Xenopus embryos</article-title>. <source>Cell</source> <volume>86</volume>: <fpage>391</fpage>–<lpage>9</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-vandeWetering1"><label>6</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van de Wetering</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Cavallo</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Dooijes</surname><given-names>D</given-names></name>, <name name-style="western"><surname>van Beest</surname><given-names>M</given-names></name>, <name name-style="western"><surname>van Es</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>1997</year>) <article-title>Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF</article-title>. <source>Cell</source> <volume>88</volume>: <fpage>789</fpage>–<lpage>99</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Zhurinsky1"><label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhurinsky</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Shtutman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ben-Ze'ev</surname><given-names>A</given-names></name> (<year>2000</year>) <article-title>Differential mechanisms of LEF/TCF family-dependent transcriptional activation by <italic>β</italic>–catenin and plakoglobin</article-title>. <source>Mol Cell Biol</source> <volume>20</volume>: <fpage>4238</fpage>–<lpage>52</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Peifer1"><label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Peifer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Polakis</surname><given-names>P</given-names></name> (<year>2000</year>) <article-title>Wnt signaling in oncogenesis and embryogenesis—a look outside the nucleus</article-title>. <source>Science</source> <volume>287</volume>: <fpage>1606</fpage>–<lpage>9</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Kimelman1"><label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kimelman</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>W</given-names></name> (<year>2006</year>) <article-title><italic>β</italic>–catenin destruction complex: insights and questions from a structural perspective</article-title>. <source>Oncogene</source> <volume>25</volume>: <fpage>7482</fpage>–<lpage>91</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Stamos1"><label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stamos</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Weis</surname><given-names>WI</given-names></name> (<year>2013</year>) <article-title>The <italic>β</italic>–catenin destruction complex</article-title>. <source>Cold Spring Harb Perspect Biol</source> <volume>5</volume>: <fpage>a007898</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Dajani1"><label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dajani</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Fraser</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Roe</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Yeo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Good</surname><given-names>VM</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>Structural basis for recruitment of glycogen synthase kinase 3<italic>β</italic> to the axin-APC scaffold complex</article-title>. <source>EMBO J</source> <volume>22</volume>: <fpage>494</fpage>–<lpage>501</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Liu1"><label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Semenov</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Baeg</surname><given-names>GH</given-names></name>, <etal>et al</etal>. (<year>2002</year>) <article-title>Control of <italic>β</italic>–catenin phosphorylation/degradation by a dual-kinase mechanism</article-title>. <source>Cell</source> <volume>108</volume>: <fpage>837</fpage>–<lpage>47</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Wu1"><label>13</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>W</given-names></name> (<year>2010</year>) <article-title>GSK3: a multifaceted kinase in Wnt signaling</article-title>. <source>Trends Biochem Sci</source> <volume>35</volume>: <fpage>161</fpage>–<lpage>8</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Rubinfeld1"><label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rubinfeld</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Robbins</surname><given-names>P</given-names></name>, <name name-style="western"><surname>El-Gamil</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Albert</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Porfiri</surname><given-names>E</given-names></name>, <etal>et al</etal>. (<year>1997</year>) <article-title>Stabilization of <italic>β</italic>–catenin by genetic defects in melanoma cell lines</article-title>. <source>Science</source> <volume>275</volume>: <fpage>1790</fpage>–<lpage>2</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Aberle1"><label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Aberle</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Bauer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Stappert</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kispert</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kemler</surname><given-names>R</given-names></name> (<year>1997</year>) <article-title><italic>β</italic>–catenin is a target for the ubiquitin-proteasome pathway</article-title>. <source>EMBO J</source> <volume>16</volume>: <fpage>3797</fpage>–<lpage>804</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Cliffe1"><label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cliffe</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hamada</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Bienz</surname><given-names>M</given-names></name> (<year>2003</year>) <article-title>A role of Dishevelled in relocating Axin to the plasma membrane during Wingless signaling</article-title>. <source>Curr Biol</source> <volume>13</volume>: <fpage>960</fpage>–<lpage>6</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Schweizer1"><label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schweizer</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Varmus</surname><given-names>H</given-names></name> (<year>2003</year>) <article-title>Wnt/Wingless signaling through <italic>β</italic>–catenin requires the function of both LRP/Arrow and frizzled classes of receptors</article-title>. <source>BMC Cell Biol</source> <volume>4</volume>: <fpage>4</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Cong1"><label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cong</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Schweizer</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Varmus</surname><given-names>H</given-names></name> (<year>2004</year>) <article-title>Wnt signals across the plasma membrane to activate the <italic>β</italic>–catenin pathway by forming oligomers containing its receptors, Frizzled and LRP</article-title>. <source>Development</source> <volume>131</volume>: <fpage>5103</fpage>–<lpage>15</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Li1"><label>19</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname><given-names>VSW</given-names></name>, <name name-style="western"><surname>Ng</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Boersema</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Low</surname><given-names>TY</given-names></name>, <name name-style="western"><surname>Karthaus</surname><given-names>WR</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Wnt signaling through inhibition of <italic>β</italic>–catenin degradation in an intact Axin1 complex</article-title>. <source>Cell</source> <volume>149</volume>: <fpage>1245</fpage>–<lpage>56</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Hernndez1"><label>20</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hernández</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Klein</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Kirschner</surname><given-names>MW</given-names></name> (<year>2012</year>) <article-title>Kinetic responses of <italic>β</italic>–catenin specify the sites of Wnt control</article-title>. <source>Science</source> <volume>338</volume>: <fpage>1337</fpage>–<lpage>40</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Markowitz1"><label>21</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Markowitz</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Bertagnolli</surname><given-names>MM</given-names></name> (<year>2009</year>) <article-title>Molecular basis of colorectal cancer</article-title>. <source>N Engl J Med</source> <volume>361</volume>: <fpage>2449</fpage>–<lpage>60</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Xing1"><label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xing</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Clements</surname><given-names>WK</given-names></name>, <name name-style="western"><surname>Kimelman</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>W</given-names></name> (<year>2003</year>) <article-title>Crystal structure of a <italic>β</italic>–catenin/axin complex suggests a mechanism for the <italic>β</italic>–catenin destruction complex</article-title>. <source>Genes Dev</source> <volume>17</volume>: <fpage>2753</fpage>–<lpage>64</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Sakanaka1"><label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sakanaka</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>LT</given-names></name> (<year>1999</year>) <article-title>Functional domains of axin. Importance of the C terminus as an oligomerization domain</article-title>. <source>J Biol Chem</source> <volume>274</volume>: <fpage>14090</fpage>–<lpage>3</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Xing2"><label>24</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xing</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Clements</surname><given-names>WK</given-names></name>, <name name-style="western"><surname>Le Trong</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Hinds</surname><given-names>TR</given-names></name>, <name name-style="western"><surname>Stenkamp</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>Crystal structure of a <italic>β</italic>–catenin/APC complex reveals a critical role for APC phosphorylation in APC function</article-title>. <source>Mol Cell</source> <volume>15</volume>: <fpage>523</fpage>–<lpage>33</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Liu2"><label>25</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Xing</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hinds</surname><given-names>TR</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>W</given-names></name> (<year>2006</year>) <article-title>The third 20 amino acid repeat is the tightest binding site of APC for <italic>β</italic>–catenin</article-title>. <source>J Mol Biol</source> <volume>360</volume>: <fpage>133</fpage>–<lpage>44</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-EklofSpink1"><label>26</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Eklof Spink</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Fridman</surname><given-names>SG</given-names></name>, <name name-style="western"><surname>Weis</surname><given-names>WI</given-names></name> (<year>2001</year>) <article-title>Molecular mechanisms of <italic>β</italic>–catenin recognition by adenomatous polyposis coli revealed by the structure of an APC-<italic>β</italic>–catenin complex</article-title>. <source>EMBO J</source> <volume>20</volume>: <fpage>6203</fpage>–<lpage>12</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Spink1"><label>27</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Spink</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Polakis</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Weis</surname><given-names>WI</given-names></name> (<year>2000</year>) <article-title>Structural basis of the Axin-adenomatous polyposis coli interaction</article-title>. <source>EMBO J</source> <volume>19</volume>: <fpage>2270</fpage>–<lpage>9</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Hedgepeth1"><label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hedgepeth</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Deardorff</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Rankin</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Klein</surname><given-names>PS</given-names></name> (<year>1999</year>) <article-title>Regulation of glycogen synthase kinase 3<italic>β</italic> and downstream Wnt signaling by axin</article-title>. <source>Mol Cell Biol</source> <volume>19</volume>: <fpage>7147</fpage>–<lpage>57</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Sobrado1"><label>29</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sobrado</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Jedlicki</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bustos</surname><given-names>VH</given-names></name>, <name name-style="western"><surname>Allende</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Allende</surname><given-names>JE</given-names></name> (<year>2005</year>) <article-title>Basic region of residues 228–231 of protein kinase CK1<italic>α</italic> is involved in its interaction with axin: binding to axin does not affect the kinase activity</article-title>. <source>J Cell Biochem</source> <volume>94</volume>: <fpage>217</fpage>–<lpage>24</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Ha1"><label>30</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ha</surname><given-names>NC</given-names></name>, <name name-style="western"><surname>Tonozuka</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Stamos</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Weis</surname><given-names>WI</given-names></name> (<year>2004</year>) <article-title>Mechanism of phosphorylation-dependent binding of APC to <italic>β</italic>–catenin and its role in <italic>β</italic>–catenin degradation</article-title>. <source>Mol Cell</source> <volume>15</volume>: <fpage>511</fpage>–<lpage>21</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Munemitsu1"><label>31</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Munemitsu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Albert</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Souza</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Rubinfeld</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Polakis</surname><given-names>P</given-names></name> (<year>1995</year>) <article-title>Regulation of intracellular <italic>β</italic>–catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>92</volume>: <fpage>3046</fpage>–<lpage>50</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Seo1"><label>32</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Seo</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Jho</surname><given-names>Eh</given-names></name> (<year>2007</year>) <article-title>Axin-independent phosphorylation of APC controls <italic>β</italic>–catenin signaling via cytoplasmic retention of <italic>β</italic>–catenin</article-title>. <source>Biochem Biophys Res Commun</source> <volume>357</volume>: <fpage>81</fpage>–<lpage>6</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Yang1"><label>33</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Evans</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>X</given-names></name>, <name name-style="western"><surname>He</surname><given-names>X</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Adenomatous polyposis coli (APC) differentially regulates <italic>β</italic>–catenin phosphorylation and ubiquitination in colon cancer cells</article-title>. <source>J Biol Chem</source> <volume>281</volume>: <fpage>17751</fpage>–<lpage>7</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Faux1"><label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Faux</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Ross</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Meeker</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Johns</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ji</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>Restoration of full-length adenomatous polyposis coli (APC) protein in a colon cancer cell line enhances cell adhesion</article-title>. <source>J Cell Sci</source> <volume>117</volume>: <fpage>427</fpage>–<lpage>39</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-SchwarzRomond1"><label>35</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schwarz-Romond</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Metcalfe</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Bienz</surname><given-names>M</given-names></name> (<year>2007</year>) <article-title>Dynamic recruitment of axin by Dishevelled protein assemblies</article-title>. <source>J Cell Sci</source> <volume>120</volume>: <fpage>2402</fpage>–<lpage>12</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Faux2"><label>36</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Faux</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Coates</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Catimel</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Cody</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Clayton</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Recruitment of ademonatous polyposis coli and <italic>β</italic>–catenin to axin-puncta</article-title>. <source>Oncogene</source> <volume>27</volume>: <fpage>5808</fpage>–<lpage>20</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Hlavacek1"><label>37</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hlavacek</surname><given-names>WS</given-names></name>, <name name-style="western"><surname>Faeder</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Blinov</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Posner</surname><given-names>RG</given-names></name>, <name name-style="western"><surname>Hucka</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Rules for modeling signal-transduction systems</article-title>. <source>Sci STKE</source> <volume>2006</volume>: <fpage>re6</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Faeder1"><label>38</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Faeder</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Blinov</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Goldstein</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Hlavacek</surname><given-names>WS</given-names></name> (<year>2005</year>) <article-title>Rule-based modeling of biochemical networks</article-title>. <source>Complexity</source> <volume>10</volume>: <fpage>22</fpage>–<lpage>41</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Faeder2"><label>39</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Faeder</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Blinov</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Hlavacek</surname><given-names>WS</given-names></name> (<year>2009</year>) <article-title>Rule-based modeling of biochemical systems with BioNetGen</article-title>. <source>Methods Mol Biol</source> <volume>500</volume>: <fpage>113</fpage>–<lpage>67</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Chylek1"><label>40</label>
<mixed-citation publication-type="other" xlink:type="simple">Chylek LA, Stites EC, Posner RG, Hlavacek WS (2013) Innovations of the rule-based modeling approach. In: Prokop A, Csukás B, Editors. Systems Biology: Integrative Biology and Simulation Tools, Volume 1. Springer.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Hlavacek2"><label>41</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hlavacek</surname><given-names>WS</given-names></name>, <name name-style="western"><surname>Faeder</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Blinov</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Goldstein</surname><given-names>B</given-names></name> (<year>2003</year>) <article-title>The complexity of complexes in signal transduction</article-title>. <source>Biotechnol Bioeng</source> <volume>84</volume>: <fpage>783</fpage>–<lpage>94</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Chylek2"><label>42</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chylek</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Blinov</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Emonet</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Faeder</surname><given-names>JR</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Guidelines for visualizing and annotating rule-based models</article-title>. <source>Mol BioSyst</source> <volume>7</volume>: <fpage>2779</fpage>–<lpage>95</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Kishida1"><label>43</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kishida</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ikeda</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kishida</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sakamoto</surname><given-names>I</given-names></name>, <etal>et al</etal>. (<year>1998</year>) <article-title>Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of <italic>β</italic>–catenin</article-title>. <source>J Biol Chem</source> <volume>273</volume>: <fpage>10823</fpage>–<lpage>6</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Frame1"><label>44</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Frame</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Cohen</surname><given-names>P</given-names></name> (<year>2001</year>) <article-title>GSK3 takes centre stage more than 20 years after its discovery</article-title>. <source>Biochem J</source> <volume>359</volume>: <fpage>1</fpage>–<lpage>16</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Rubinfeld2"><label>45</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rubinfeld</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Tice</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Polakis</surname><given-names>P</given-names></name> (<year>2001</year>) <article-title>Axin-dependent phosphorylation of the adenomatous polyposis coli protein mediated by casein kinase 1<italic>ε</italic></article-title>. <source>J Biol Chem</source> <volume>276</volume>: <fpage>39037</fpage>–<lpage>45</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Ikeda1"><label>46</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ikeda</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kishida</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Matsuura</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Usui</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kikuchi</surname><given-names>A</given-names></name> (<year>2000</year>) <article-title>GSK-3<italic>β</italic>-dependent phosphorylation of adenomatous polyposis coli gene product can be modulated by <italic>β</italic>–catenin and protein phosphatase 2A complexed with Axin</article-title>. <source>Oncogene</source> <volume>19</volume>: <fpage>537</fpage>–<lpage>45</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Crothers1"><label>47</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Crothers</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Metzger</surname><given-names>H</given-names></name> (<year>1972</year>) <article-title>The influence of polyvalency on the binding properties of antibodies</article-title>. <source>Immunochemistry</source> <volume>9</volume>: <fpage>341</fpage>–<lpage>57</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Smith1"><label>48</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Smith</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Bryan</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Hill</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Markowitz</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>1993</year>) <article-title>The APC gene product in normal and tumor cells</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>90</volume>: <fpage>2846</fpage>–<lpage>50</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Yang2"><label>49</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hlavacek</surname><given-names>WS</given-names></name> (<year>2011</year>) <article-title>Scaffold-mediated nucleation of protein signaling complexes: elementary principles</article-title>. <source>Math Biosci</source> <volume>232</volume>: <fpage>164</fpage>–<lpage>73</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Douglass1"><label>50</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Douglass</surname><given-names>EF</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Miller</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Sparer</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Shapiro</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Spiegel</surname><given-names>DA</given-names></name> (<year>2013</year>) <article-title>A comprehensive mathematical model for three-body binding equilibria</article-title>. <source>J Am Chem Soc</source> <volume>135</volume>: <fpage>6092</fpage>–<lpage>9</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Behrens2"><label>51</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Behrens</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Jerchow</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Würtele</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Grimm</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Asbrand</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>1998</year>) <article-title>Functional interaction of an axin homolog, conductin, with <italic>β</italic>–catenin, APC, and GSK3<italic>β</italic></article-title>. <source>Science</source> <volume>280</volume>: <fpage>596</fpage>–<lpage>9</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Hart1"><label>52</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hart</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>de los Santos</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Albert</surname><given-names>IN</given-names></name>, <name name-style="western"><surname>Rubinfeld</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Polakis</surname><given-names>P</given-names></name> (<year>1998</year>) <article-title>Downregulation of <italic>β</italic>–catenin by human Axin and its association with the APC tumor suppressor, <italic>β</italic>–catenin and GSK3<italic>β</italic></article-title>. <source>Curr Biol</source> <volume>8</volume>: <fpage>573</fpage>–<lpage>81</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Lee1"><label>53</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Salic</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Krüger</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Heinrich</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Kirschner</surname><given-names>MW</given-names></name> (<year>2003</year>) <article-title>The roles of APC and Axin derived from experimental and theoretical analysis of the Wnt pathway</article-title>. <source>PLoS Biol</source> <volume>1</volume>: <fpage>E10</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Graham1"><label>54</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Graham</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Weaver</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mao</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Kimelman</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>W</given-names></name> (<year>2000</year>) <article-title>Crystal structure of a <italic>β</italic>–catenin/Tcf complex</article-title>. <source>Cell</source> <volume>103</volume>: <fpage>885</fpage>–<lpage>96</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-vonKries1"><label>55</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>von Kries</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Winbeck</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Asbrand</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Schwarz-Romond</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Sochnikova</surname><given-names>N</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Hot spots in <italic>β</italic>–catenin for interactions with LEF-1, conductin and APC</article-title>. <source>Nat Struct Biol</source> <volume>7</volume>: <fpage>800</fpage>–<lpage>7</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-OBrien1"><label>56</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>O'Brien</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Rugman</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Renzoni</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Layton</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Handa</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Alternative modes of binding of proteins with tandem SH2 domains</article-title>. <source>Protein Sci</source> <volume>9</volume>: <fpage>570</fpage>–<lpage>9</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Barua1"><label>57</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Barua</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Faeder</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Haugh</surname><given-names>JM</given-names></name> (<year>2008</year>) <article-title>Computational models of tandem SRC homology 2 domain interactions and application to phosphoinositide 3-kinase</article-title>. <source>J Biol Chem</source> <volume>283</volume>: <fpage>7338</fpage>–<lpage>45</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Kuriyan1"><label>58</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kuriyan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Cowburn</surname><given-names>D</given-names></name> (<year>1997</year>) <article-title>Modular peptide recognition domains in eukaryotic signaling</article-title>. <source>Annu Rev Biophys Biomol Struct</source> <volume>26</volume>: <fpage>259</fpage>–<lpage>88</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Tan1"><label>59</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tan</surname><given-names>CW</given-names></name>, <name name-style="western"><surname>Gardiner</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Hirokawa</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Layton</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>DW</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Wnt signalling pathway parameters for mammalian cells</article-title>. <source>PLOS ONE</source> <volume>7</volume>: <fpage>e31882</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Jacobson1"><label>60</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jacobson</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Stockmayer</surname><given-names>WH</given-names></name> (<year>1950</year>) <article-title>Intramolecular reaction in polycondensations. I. The theory of linear systems</article-title>. <source>J Chem Phys</source> <volume>18</volume>: <fpage>1600</fpage>–<lpage>6</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Bienz1"><label>61</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bienz</surname><given-names>M</given-names></name> (<year>2002</year>) <article-title>The subcellular destinations of APC proteins</article-title>. <source>Nat Rev Mol Cell Biol</source> <volume>3</volume>: <fpage>328</fpage>–<lpage>38</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Henderson1"><label>62</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Henderson</surname><given-names>BR</given-names></name> (<year>2000</year>) <article-title>Nuclear-cytoplasmic shuttling of APC regulates <italic>β</italic>–catenin subcellular localization and turnover</article-title>. <source>Nat Cell Biol</source> <volume>2</volume>: <fpage>653</fpage>–<lpage>60</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-RosinArbesfeld1"><label>63</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rosin-Arbesfeld</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Townsley</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Bienz</surname><given-names>M</given-names></name> (<year>2000</year>) <article-title>The APC tumour suppressor has a nuclear export function</article-title>. <source>Nature</source> <volume>406</volume>: <fpage>1009</fpage>–<lpage>12</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Hlsken1"><label>64</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hülsken</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Birchmeier</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Behrens</surname><given-names>J</given-names></name> (<year>1994</year>) <article-title>E-cadherin and APC compete for the interaction with <italic>β</italic>–catenin and the cytoskeleton</article-title>. <source>J Cell Biol</source> <volume>127</volume>: <fpage>2061</fpage>–<lpage>9</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Behrend1"><label>65</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Behrend</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Milne</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Stöter</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Deppert</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Campbell</surname><given-names>LE</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>IC261, a specific inhibitor of the protein kinases casein kinase 1-delta and -epsilon, triggers the mitotic checkpoint and induces p53-dependent postmitotic effects</article-title>. <source>Oncogene</source> <volume>19</volume>: <fpage>5303</fpage>–<lpage>13</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Badura1"><label>66</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Badura</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Swanson</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Adamowicz</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Adams</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Cianfrogna</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>An inhibitor of casein kinase I<italic>ε</italic> induces phase delays in circadian rhythms under free-running and entrained conditions</article-title>. <source>J Pharmacol Exp Ther</source> <volume>322</volume>: <fpage>730</fpage>–<lpage>8</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Walton1"><label>67</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Walton</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Fisher</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Rubitski</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Marconi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Meng</surname><given-names>Q</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Selective inhibition of casein kinase 1<italic>ε</italic> minimally alters circadian clock period</article-title>. <source>J Pharmacol Exp Ther</source> <volume>330</volume>: <fpage>430</fpage>–<lpage>9</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Ikeda2"><label>68</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ikeda</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kishida</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Murai</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Koyama</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>1998</year>) <article-title>Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3<italic>β</italic> and <italic>β</italic>–catenin and promotes GSK-3<italic>β</italic>-dependent phosphorylation of <italic>β</italic>–catenin</article-title>. <source>EMBO J</source> <volume>17</volume>: <fpage>1371</fpage>–<lpage>84</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Gutenkunst1"><label>69</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gutenkunst</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Waterfall</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Casey</surname><given-names>FP</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Myers</surname><given-names>CR</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Universally sloppy parameter sensitivities in systems biology models</article-title>. <source>PLoS Comput Biol</source> <volume>3</volume>: <fpage>1871</fpage>–<lpage>8</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Blinov1"><label>70</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Blinov</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Faeder</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Goldstein</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Hlavacek</surname><given-names>WS</given-names></name> (<year>2004</year>) <article-title>BioNetGen: software for rule-based modeling of signal transduction based on the interactions of molecular domains</article-title>. <source>Bioinformatics</source> <volume>20</volume>: <fpage>3289</fpage>–<lpage>91</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Xu1"><label>71</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Faeder</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Marai</surname><given-names>GE</given-names></name> (<year>2011</year>) <article-title>RuleBender: a visual interface for rule-based modeling</article-title>. <source>Bioinformatics</source> <volume>27</volume>: <fpage>1721</fpage>–<lpage>2</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Cohen1"><label>72</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cohen</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hindmarsh</surname><given-names>A</given-names></name> (<year>1996</year>) <article-title>CVODE, a stiff/nonstiff ODE solver in C</article-title>. <source>Comp Phys</source> <volume>10</volume>: <fpage>138</fpage>–<lpage>43</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Hindmarsh1"><label>73</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hindmarsh</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Grant</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Serban</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>SUNDIALS: Suite of nonlinear and differential/algebraic equation solvers</article-title>. <source>ACM Trans Math Softw</source> <volume>31</volume>: <fpage>363</fpage>–<lpage>96</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Sadot1"><label>74</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sadot</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Conacci-Sorrell</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zhurinsky</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Shnizer</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lando</surname><given-names>Z</given-names></name>, <etal>et al</etal>. (<year>2002</year>) <article-title>Regulation of S33/S37 phosphorylated <italic>β</italic>–catenin in normal and transformed cells</article-title>. <source>J Cell Sci</source> <volume>115</volume>: <fpage>2771</fpage>–<lpage>80</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Jain1"><label>75</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jain</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Bairoch</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Duvaud</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Phan</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Redaschi</surname><given-names>N</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Infrastructure for the life sciences: design and implementation of the UniProt website</article-title>. <source>BMC Bioinformatics</source> <volume>10</volume>: <fpage>136</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Amberger1"><label>76</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Amberger</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bocchini</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hamosh</surname><given-names>A</given-names></name> (<year>2011</year>) <article-title>A new face and new challenges for Online Medelian Inheritance in Man (OMIM)</article-title>. <source>Hum Mut</source> <volume>32</volume>: <fpage>564</fpage>–<lpage>7</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003217-Finn1"><label>77</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Finn</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Mistry</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tate</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Coggill</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Heger</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>The Pfam protein families database</article-title>. <source>Nucleic Acids Res</source> <volume>38</volume>: <fpage>D211</fpage>–<lpage>22</lpage>.</mixed-citation>
</ref>
</ref-list></back>
</article>